 
 
 
Protocol J1P -MC-KFAJ( a) 
 
 
A Randomized, Doub le-Blind, Placebo -Controlled, 
Phase 2 St udy of LY3471851 (NKTR -358) in Adults 
with Systemic Lupus Erythem atosus 
 
[STUDY_ID_REMOVED]  
 
Approv al Date:  19August2020  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 1 Approval Date: 19 -Aug-2020 GMT  Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clin ical 
investigation of LY3471851 , unless such persons are bound by a confidentiality agreement with  
Eli Lilly and Company or its subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidenti al information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not b e reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries.  
 
Protocol Title:  A Randomized, Double -Blind, Placebo -Controlled, Phase 2 Study of 
LY3471851 (NKTR -358) in Adults with Systemic Lupus Erythematosus  
Protocol Number:  J1P-MC-KFAJ  
Amendment Number: a 
Compound : LY3471851  
Study Phase:  2 
Short Title:  A Randomized, Double -Blind, Placebo -Controlled, Phase 2 Study of  
LY3471851 (NKTR -358) in Adults with Systemic Lupus Erythematosus  
Acronym : ISLAND -SLE 
Sponsor Name:  Eli Lilly and Company  
Legal Registered Address:  Indianapolis, Indiana USA 46285  
Regulatory Agency Identifier Numbers  
IND 132275  
EudraCT  2019 -003323 -38 
Approval Date:  Protocol  Amendment (a) Electronically  Signed and Approved  by Lilly  on date 
provided below.  
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 2 Medical Monitor Name and Contact Information will be provided separately . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 3 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Document  Date  
KFAJ  Protocol   
Amendment [a]  
This amendment occurred before any study parti cipant was consented or dosed at any study site 
in Europe.  
Overall Rationale for the Amendment:  
The purpose of this protocol amendment is to correct typographical errors  and clarify study 
procedures and statistical analysis plans  in response to European r egulator y agency  feedback .  
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
1.2. Schema  ................................ ................................ ................................ ............................ 11 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 12 
2. Introduction  ................................ ................................ ................................ ................... 25 
2.1. Study Rationale  ................................ ................................ ................................ ............... 25 
2.2. Background  ................................ ................................ ................................ ..................... 25 
2.3. Benefit/Risk Assess ment  ................................ ................................ ................................ 26 
3. Objectives and Endpoints  ................................ ................................ ............................ 27 
4. Study Design  ................................ ................................ ................................ .................. 29 
4.1. Overall Desig n ................................ ................................ ................................ ................ 29 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 30 
4.2.1.  Participant Input into Design  ................................ ................................ .......................... 31 
4.3. Justification for Dose  ................................ ................................ ................................ ......32 
4.4. End-of-Study Definition  ................................ ................................ ................................ .33 
5. Study Population  ................................ ................................ ................................ ........... 34 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 34 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 35 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .39 
5.4. Screen Failures  ................................ ................................ ................................ ................ 39 
5.4.1.  Allowed Retesting of Screening Investigations  ................................ .............................. 40 
5.4.2.  Rescreening of Individuals Who Failed Screening  ................................ ......................... 40 
6. Study Intervention  ................................ ................................ ................................ ........ 41 
6.1. Study Interventions Administered  ................................ ................................ .................. 41 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 41 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 42 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 43 
6.5. Concomitant Therapy  ................................ ................................ ................................ .....44 
6.5.1.  Corticosteroid Management Program  ................................ ................................ ............. 44 
  
6.7. Intervention after the End of the Study  ................................ ................................ ........... 46 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 47 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 47 
7.1.1.  Criteria for Permanent Discontinuation of Study Drug  ................................ .................. 47 
7.1.2.  Criteria for Temporary Interruption (Withholding) of Study Drug  ................................ 50 
7.2. Participant Discontinuation /Withdrawal from the Study  ................................ ................ 50 
7.2.1.  Discontinuation of Inadvertently Enrolled Participants  ................................ .................. 51 
7.3. Lost to Follow up  ................................ ................................ ................................ ............ 51 
8. Study Assessments and Procedures ................................ ................................ ............. 52 
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 5 8.1. Efficacy Assessments  ................................ ................................ ................................ .....52 
8.1.1.  Primary Efficacy Outcome Measure: SLEDAI -4 ................................ ........................... 52 
8.1.2.  Secondary E fficacy Outcome Measures  ................................ ................................ ......... 52 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 53 
8.2.1.  Vital Signs  ................................ ................................ ................................ ....................... 54 
8.2.2.  Physical Examinations  ................................ ................................ ................................ ....54 
8.2.3.  Electrocardiograms  ................................ ................................ ................................ ......... 55 
8.2.4.  Chest Radiography  ................................ ................................ ................................ .......... 55 
8.2.5.  Laboratory Tests  ................................ ................................ ................................ ............. 56 
8.2.6.  Tuberculosis Testing and Monitoring  ................................ ................................ ............. 57 
8.2.7.  Hepatitis B Testing and Monitoring  ................................ ................................ ............... 58 
8.2.8.  Hepatitis C Testing and Monitoring  ................................ ................................ ............... 59 
8.2.9.  Hepatic Safety Monitoring  ................................ ................................ .............................. 60 
8.2.10.  Suicidal Ideation and Behavior Risk Monitoring  ................................ ........................... 61 
8.2.11.  Injection Site Assessment  ................................ ................................ ............................... 62 
8.3. Adverse Events and Serious Adverse Events  ................................ ................................ .62 
8.3.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ................................ ..................... 63 
8.3.2.  Method of Detecting AEs and SAEs  ................................ ................................ .............. 63 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ ........................... 64 
8.3.4.  Regulatory Reporting Requirements for SAEs  ................................ ............................... 64 
8.3.5.  Pregnancy  ................................ ................................ ................................ ........................ 64 
  
8.3.7.  Complaint Handling  ................................ ................................ ................................ ........ 65 
8.4. Treatment of Overdose  ................................ ................................ ................................ ...66 
8.5. Pharmacokinetics  ................................ ................................ ................................ ............ 66 
  
  
  
  
8.10.  Medical Resource Utilization and Health Economics  ................................ .................... 68 
9. Statistical Considerations  ................................ ................................ ............................. 69 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....69 
9.2. Sample Size Determination  ................................ ................................ ............................ 69 
9.3. Populations for Analyses  ................................ ................................ ................................ 69 
9.4. Statistical Analyses  ................................ ................................ ................................ ......... 69 
9.4.1.  General Considerations  ................................ ................................ ................................ ...69 
9.4.2.  Primary Endpoints  ................................ ................................ ................................ .......... 71 
9.4.3.  Secondary Efficacy Endpoints  ................................ ................................ ........................ 71 
  
9.4.5.  Safety Analyses  ................................ ................................ ................................ ............... 72 
  
  
9.6. Data Monitoring Committee (DMC)  ................................ ................................ .............. 74 
10. Supporting Documentation and Operational Considerations  ................................ ..75 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 6 10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 75 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 75 
10.1.2.  Financial Disclosure ................................ ................................ ................................ ........ 75 
10.1.3.  Informed Consent Process  ................................ ................................ .............................. 76 
10.1.4.  Data Protection ................................ ................................ ................................ ................ 76 
10.1.5.  Committees Structure ................................ ................................ ................................ ......76 
10.1.6.  Dissemination of Clinical Study Data ................................ ................................ ............. 77 
10.1.7.  Data Quality Assurance  ................................ ................................ ................................ ..77 
10.1.8.  Source Documents  ................................ ................................ ................................ .......... 79 
10.1.9.  Study and Site Start and Closure  ................................ ................................ .................... 79 
10.1.10.  Publication Policy  ................................ ................................ ................................ ........... 80 
10.1.11.  Investigator Information  ................................ ................................ ................................ .80 
 
10.2.  Appendix 2: Clinical Lab oratory Tests  ................................ ................................ ........... 82 
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evalua ting, Follow -up, and Reporting  ................................ ......................... 86 
10.3.1.  Definition of AE  ................................ ................................ ................................ ............. 86 
10.3.2.  Definition of SAE  ................................ ................................ ................................ ........... 87 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ ................................ 88 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 89 
10.4.  Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy Information  ................................ ................................ ................................ ...91 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 91 
10.4.2.  Contraception  ................................ ................................ ................................ .................. 92 
10.4.3.  Collection of Pregnancy Information ................................ ................................ .............. 92 
10.5.  Appendix 5: Liver Safety: Hepatic Monitoring Tests  ................................ .................... 94 
10.6.  Appendix 6: Examples of Infections That May Be Considered 
Opportunistic in the Setting of Biologic Therapy  ................................ ........................... 95 
10.7.  Appendix 7: Efficacy and Patient -Reported Outcomes 
Assessments  ................................ ................................ ................................ .................... 97 
10.7.1.  British Isles Lupus Assessment Group 2004 (BILAG -2004)  ................................ ......... 97 
  
 
10.7.3.  Physician’s Global Assessment (PGA) of Disease Activity – 
Visual Analog Scale  ................................ ................................ ................................ ........ 97 
10.7.4.  Systemic Lupus Erythematosus Disease Activity Index 2000 
(SLEDAI -2K) ................................ ................................ ................................ ................. 97 
10.7.5.  Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) Flare Index  ................................ ................................ ................................ ....98 
  
 
 
  
  
 
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 7   
 
 
 
 
 
 
 
 
 
10.8.  Appendix 8: Abbreviations  ................................ ................................ ........................... 101 
11. References  ................................ ................................ ................................ .................... 105 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 10 Intervention Groups  and Duration : 
Participants will be randomized in a 1:1:1:1 ratio  to receive  one of the following 
study interventions:  
●   LY3471851  Q2W  
●   LY3471851  Q2W  
●   LY3471851  Q2W , or 
●  placebo Q2W.  
Data Monitoring Committee:  No 
 
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 22 Abbreviations : ACR  = American College of Rheumatology ;  
 BILAG 
= British Isles Lupus Assessment Group;  C-SSRS = Columbia –Suicide Severity 
Rating Scale ; DNA = deoxyribonucleic acid; ECG = electrocardiogram; ETV = early termination visit;  
;HBV = h epatitis B  virus;  IL = interleukin ;  
 QIDS -SR16 = 16-Item Quick Inventory of Depressive Symptomatology –Self Report ;  
 SLE = systemic lupus erythematosus ; SLEDAI -2K = Systemic Lupus Erythematosus Disease Activity Index 
2000;  V = visit; VAS = visual analog scale .   
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 25 2. Introduction  
2.1. Study Rationale  
LY3471851 (also known as NKTR -358) is a polyethylene glycol (PEG) -conjugated recombinant 
human interleukin  (IL)-2 (rhIL -2) with the capacity to promote the expansion and activation of 
regulatory T  cells (Tregs) with relatively minimal effect on conventional T cells (Tcons). When 
compared to rhIL -2, PEGylation results in prolonged systemic exposure  and improved binding to 
the high affinity IL -2 receptor most present on regulatory T cells ( Tregs ). In preliminary clinical 
studies, low -dose recombinant human IL -2 was shown to reverse IL-2 deficiency and the Treg 
deficit typically observed in patients wit h systemic lupus erythematosus (SLE ) (von Spee -Mayer 
et al. 2016 ). Moreover, low -dose IL -2 therapy was associated with improvements in SELENA -
SLEDAI and SLE Response Index (S RI-4 response) (He et al. 2016 , He et al. 2020 ). 
Study J1P-MC-KFAJ  (KFAJ) is a Phase 2 study to evaluate the efficacy and safety of 
LY3471851 in adult patients  with SLE. Results of this study will be used to guide the dose 
selection for future studies and to further characterize the benefit/risk profile of LY3471851 . 
2.2. Background  
Systemic lupus erythematosus is a chronic, debilitating, autoimmune disease characterized by the 
presence of autoreactive B cells and elevated levels of autoantibodies . The disease can affect 
multiple organ systems and follows an unpredictable clinical cou rse. Patients may present with 
arthralgia , arthritis, skin rash, alopecia, oral ulcers, pleuritis, pericarditis, nephritis, vasculitis, 
stroke, seizure, leukopenia, thrombocytopenia, anemia, photosensitivity, and the presence of 
autoantibodies directed to nuclear antigens. More than 60% of patients with SLE will develop 
clinically detectable organ damage about 4 years  after the diagnosis, as measured by the 
Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage 
Index (SDI ) (Cooper et al. 2007) . 
The standard -of-care for SLE varies widely and currently includes the use of corticosteroids, 
nonsteroidal anti -inflammatory drugs  (NSAIDs) , antimalarial medication, cytotoxic agents, and 
immunosuppressants. Unfortunately, the morbi dity of the disease remains substantial, as 
measured by various tools for evaluating health -related quality of life, loss of work productivity, 
pain, and fatigue (Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for 
Fatigue 2007; Özel and  Argon 2015) . A meta -analysis involving more than 27,000  patients 
showed that SLE patients had a 3-fold increase in risk of death compared with the general 
population (Yurkovich et al. 2014).  Patients with SLE need better treatment options.  
The dysfunction in Treg cell biology has been proposed as a key defect in SLE, leading to the 
breakdown of immune self -tolerance  (Ohl and Tenbrock 2015) . The goal of LY3471851 therapy 
is to increase Treg number and function, with a minimal effect on Tcons  and natural killer ( NK) 
cells. 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 26 2.3. Benefit/Risk Assessment  
The Investigator’s Brochure (IB) designates l ocal injection site reactions  (ISR)  as an identified 
risk of LY3471851 , based on reports of primarily low -grade injection site reactions  in the Phase 
1 studies . Reports of cytokine release syndrome (CRS ) and clinical symptom complex attributed 
to elevated cytokine levels were of Grade 1 severity . Eosinophilia without evidence of target 
organ damage was observed in some participants  in the Phase 1 study in SLE . The safety 
findings from Phase 1 studies  show ed no evidence of adverse events characteristic of capillary 
leak syndrome, increased risk of infection, worsening or new onset autoimmune disease, cardiac 
disorders (cardiac rhythm disturbances, angina, or myocardial infarction), pulmonary disorders, 
central nervous system effects, or severe anemia/thrombocytopenia known to be associated with 
high-dose IL -2 (aldesleukin).  
To minimize study participant risk in Study KFAJ , enrolled p articipants will receive st udy drug 
doses in the clinic to enable appropriate pre -dose safety assessments and post -dose monitoring. 
The routine safety assessments  include physical exam inations, clinical safety laboratory tests 
(including hematology and chemistry), suicidality/self -harm and depression evaluations, and 
collection of vital signs and  spontaneously reported adverse events . The study design includes a 
post-treatment follow -up period with at least one study visit for safety assessments.  
 
 
 
 
 
 
 
In addition, based on observations of treatment -related biliary hyperplasia noted in nonclinical 
studies, as described in the IB, investigators should be aware of the possible occurrence of 
treatment -related hepatobiliary changes that could possibly include cholestasis. The protocol 
includes  hepatic -related laboratory  testing to support intensive monitoring for symptoms and 
physical signs suggestive of liver or biliary toxicity, including jau ndice, scleral icterus, and 
pruritis. See also Section 8.2.9 . 
Ongoing study -level monitoring of safety data will be performed , as described in Section 8.2. 
 
 
The efficacy of LY3471851 in SLE has not been established . Participants may benefit by 
receiving personal health information from the physical  examinations  and from other routine 
safety assessments performed in this study.  
In summary, in the context of the cumulative knowledge for LY3471851 , the benefit/risk balance 
for this study is assessed to be  acceptable for testing in Phase 2 . 
More detailed information about the known and expected benefits and risks and reasonab ly 
expected adverse events of LY3471851 may be found in the IB. 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 29 4. Study Design  
4.1. Overall  Design  
Study KFAJ is a multicenter, ran domized, double -blind, placebo -controlled, parallel -group 
Phase  2 study to evaluate the efficacy and safety of LY3471851 in adult study participants with 
at least moderately active SLE. The study has 3 required study periods  and an optional 
prescreening period . A schematic of the study design is presented  in Section 1.2. 
Optional prescreening period  
Study participants must have positive antinuclear ,  at 
Visit 1 to be eligible for randomization at Visit 2. The optional prescreening visit (Visit  601) is 
intended for those investigators who opt for central laboratory assessment of the prospective 
particip ant’s antinuclear antibodies  (ANA) ,  status before full 
screening activities are initiated.  
If opted for, the prescreening determination of ANA ,  status 
will be described in an appropriate informed consent form ( ICF). Informed consent for the 
prescreening activities will be obtained, a participant identification number will be assigned, and 
samples for specified laboratory tests will be obtained. The optional prescreening visit can be 
repeated 2  times (no more)  per participant , with a minimum of 4 weeks between visits. Repeated 
visits in the prescreening visit will not require re -consenting or assignment of a new participant 
identification number.  
Note: If the optional prescreening  is opted for, central laboratory testing for ANA , 
 is still required as part of the screening procedures 
conducted at Visit 1 . Participants with negative results at Visit 1 will not be el igible for 
enrollment, despite positive values in prescreening.  
Screening period  
The required screening period begins with Visit 1, which occurs within 5 weeks before the 
planned randomization visit. If the participant had an optional prescreening visit, an assessment 
of ANA , will be repeated at Visit  1 for confirmation of 
study eligibility. The main Study KFAJ ICF will be signe d before Visit 1 procedures are 
performed. A participant identification number will be assigned  at Visit 1, if one was not 
assigned at Visit 601. Participant eligibility will be reviewed and confirmed by an eligibility 
review committee prior to randomizati on. 
Participants found to be eligible according to all  of the study entry criteria will be randomly 
assigned in a 1:1:1:1 ratio to receive one of the following study interventions : 
●   LY3471851  every 2 weeks (Q2W)  
●   LY3471851  Q2W  
●   LY3471851  Q2W, or  
●  placebo Q2W.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 30  
 Study interventions  
will be administered via subcutaneous injection ( SC). 
Double -blind treatment period  
Randomized p articipants will begin the double -blind, placebo -controlled, 24 -week treat ment 
period at Visit 2. Participants  will receive the first dose of the assigned study intervention at that 
visit and will continue to receive doses through the last scheduled dosing visit  specified  in the 
Schedule of Activities  (SoA, Section 1.3). Participants will maintain their usual standard -of-care 
medication regimen for SLE and for  other diseases throughout the study, unless these medication 
regimens are specifically excluded by the  study entry criteria. Safety and efficacy assessments 
and laboratory sample collections will be performed as specified in the SoA. 
Follow -up period  
All participants will have a post -treatment follow -up visit (Visit 801) for safety assessments . 
Randomized participants who were positive for hepatitis B core antigen ( anti-HBc) at screening  
will have one additional post -treatment follow -up visit (Visit 802) . 
Early discontinuation  
Participants who permanently discontinue the study drug early  or withdraw from the study  
(Section 7) will undergo early termination procedures, including an early termination visit (ETV) 
and the post -treatment follow -up visits specifi ed in the SOA.  
4.2. Scientific Rationale for Study Design  
SLED AI-4 response as the primary endpoint  
The primary endpoint is the proportion of participants who achieve a SLEDAI -4 response at 
Week  24 (Section 8.1.1 ). The selection  of SLEDAI -4 for the primary endpoint  measure  was 
based on analyses from 2 recent SLE Phase  3 studies involving more than 2200 patients in a 
similar patient population (Isenberg et al. 2016; Merrill et al. 2016). The purpose of those 
analy ses was to characterize the clinical  signs and  symptoms most responsible for achieving 
responder status with Systemic Lupus Erythematosus Responder Index -5 (SRI -5), and then to 
use this information to design a more efficient study with clinically relevant endpoints (Kalunian 
et al. 2018). The primary endpoint of those 2 recent studies required a 5 -point reduction in 
SLEDAI with no worsening in British Isles Lupus Assessment Group  (BILAG) score or 
Physician’s Global Assessment of Disease Activity (P GA). The analyses found that fewer than 
1% of the study participants failed on SRI -5 due to BILAG or PGA worsening after achieving a 
≥5-point reduction in SLEDAI . Also , in the belimumab phase 3 SLE trials  (as reported in 
Arthritis Advisory Committee meetin g briefing document 2010) , the proportion of patients with 
a ≥4-point reduction in SLEDAI that failed to achieve a Systemic Lupus Erythematosus 
Responder Index -4 (SRI-4) due to worsening of the BILAG or PGA ranged from 0.3 % to 2.2%  
(Kalunian et al. 2018 ). These data provide a rationale to focus on SLEDAI as the primary driver 
of clinical response. A 4 -point reduction in SLEDAI is considered clinically meaningful and 
serves as the basis for the primary endpoint of SLEDAI -4 (Gladman et al. 2000).  
  
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 31 Appropriat eness of study population  
Patients with at least moderately active SLE are an appropriate study population for a novel 
investigational product with immunomodulating properties. The study entry criteria will enable 
enrollment of patients who are representat ive of the general population of patients with at least 
moderately active SLE as defined by Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) ≥6 during screening and ≥4 for clinical features at randomization  before 
administration of study drug. This SLEDAI cutoff has been used in other Phase 2 studies of SLE 
(van Vollenhoven et al. 2018; Wallace et al. 2018).  
Choice of control and number of treatment groups  
A double -blind, placebo -controlled design limits bias for both participant  assessments and 
investigator assessments and enables a clearer interpretation of the effects of active drug. The 
selection of placebo as a comparator for this study is warranted because there are few approved 
therapies for SLE and because study participants will be pe rmitted to receive concomitant 
standard -of-care therapies. The multiple active dose levels will allow for an evaluation of safety 
and efficacy across a broad dose range and so provide information to guide dose selection for 
future studies.  
Duration of trea tment period and post -treatment follow -up 
Evaluation of measures of efficacy at the Week 24 time point is consistent with the duration of 
treatment at the primary endpoint for proof -of-concept studies of other interventions for SLE 
(Furie et al. 2017; van Vollenhoven et al. 2018; Wallace et al. 2018).  
In longer studies, SLE efficacy outcomes at Week 24 are similar to those observed at Week 52, 
which is the time point  typically used for registration studies (Furie et al. 2011; Navarra et al. 
2011; Isenberg e t al. 2016; Merrill et al. 2016). Clinically meaningful effects were observed 
earlier than 24 weeks in open -label SLE studies of low -dose IL -2 formulations (He et al. 2016 
[rhIL -2Ser125 ]; Rosenzwajg et al. 2019 [aldesleukin and ILT -101]), which are hypothe sized  to 
work through a mechanism of action similar to that of LY3471851 . 
A post -treatment study visit will occur at Week 30, which is 8 weeks after the last dose of 
investigational product and corresponds to approximately 5 half -lives . 
Optional prescreeni ng period  
An optional prescreening period was included in the study design to reduce the number of screen 
failures. In previous studies of SLE, the absence of autoantibodies , as assessed by the  central 
laboratory  during the screening period, has been a major reason for screening failures.  
4.2.1.  Participant Input into Design  
The sponsor involved patients in the design of this study by engaging patients in simulations and 
other face -to-face or virtual collaborative events  for related SLE trials . The insights gai ned from 
these events were used to ensure that this study design is supportive of the well -being of the 
study participants and that the study procedures can be implemented effectively at the 
investigative sites . 
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 32 4.3. Justification for Dose  
Dose selection  
The doses were selected based on evaluation of clinical safety, pharmacokinetic ( PK), and 
pharmacodynamic (PD) data from a single -ascending dose study in healthy volunteers (SAD , 
Study 16-358-01), a multiple -ascending dose study in SLE patients (MAD , Study  17-358-02), 
and on nonclinical toxicology data.  
The available clinical safety data,  
 supports 
continued development over a longer time course in Phase 2 , given the safety monitoring 
planned for individual participants and the planned safety data reviews (Section 8.2). 
The lowest dose  is predicted to achieve exposures that are within the range of exposures 
achieved with the  dose s previously administered in the SAD and MAD 
studies. These doses were associated with pharmacological effects. For example, up to a  
 from baseline was observed in the percentage of CD25 bright  Tregs, with a similar 
fold change in absolu te numbers of CD25 bright  Tregs reported . 
The highest dose  is predicted to achieve exposures that are similar to a dose of 
 the highest dose tested in the MAD study . This dose was associated with 
pharmacological effects; increases in CD25 bright  Tregs and total Tregs were observed at this 
dose. An approximate   increase from baseline was observed in the absolute 
numbers of CD25 bright  Tregs reported, which did not return to baseline between doses. 
The numbers of NK cells were highly variable across patients, with an increase in the absolute 
numbers of NK cells observed   
 
 
 
 
 
An intermediate dose  will also be evaluated . This dose is predicted to achieve 
exposures that are similar to a dose  tested in both the SAD and the MAD 
studies. In the MAD study, the  dose was associated with increases in CD25 bright  Tregs 
and total Tregs; an  approximate  increase from baseline was observed in the 
absolute numbers of CD25 bright  Tregs reported  after each of the three doses , which did not return 
to baseline between doses. The re was minimal effect on absolute  numbers of NK cells at this 
dose level.  
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 33 4.4. End-of-Study  Definition  
A participant is considered to have completed the study if he  or she has completed all required 
periods  of the study , including the last visit  or the last scheduled procedure shown in the SoA 
(Section 1.3). 
The “end of the study ” is defined as the date of the last visit or last scheduled procedure shown 
in the SoA for the last participant in the study  globally.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 34 5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eli gibility criteria. Participant eligibility will be reviewed and confirmed by an eligibility 
review committee prior to randomization.  
The investigator will maintain a screening log to record details of all participants screened and to 
confirm eligibility or  record reasons for screening failure, as applicable.  
For rescreening and retesting activities within the screening period, see Section 5.4. 
5.1. Inclusion Criteria  
Patients  will be  included in the study only if all of the following inclusion criteria are met : 
Informed  consent  
[1]  Are c apable of giving signed informed consent as described in Appendix 10.1, which 
includes compliance with the requirements and restrictions listed in th e ICF and in this 
protocol . 
Participant characteristics  
[2]  Are male or female patients from 18 to 65 years of age (inclusive) , at the time of screening  
(Visit 1) . 
Note:  Contraceptive use by men or women should be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies.  For the 
contraception requirements  of this protocol , see Appendix  10.4. 
SLE -related inclusion criteria  
[3]  Have received a clinical diagnosis of SLE at least 24 weeks before the screening  visit 
(Visit  1). 
[4]  Have documentation of having met at least 4  of the 11 Revised Criteria for Classification of 
Systemic Lupus Erythematosus according to the 1997 Update of the 1982 ACR (Tan et al. 
1982; Hochberg 1997)  before randomization . 
[5]  Have a positive ANA  (titer ≥1:80) and/or a positive  
antibody test at screening  (Visit 1 ) as assessed by the central laboratory . 
Note:  This criterion must be assessed on the samples collected  at Visit 1, not the 
prescreening samples collected at Visit 601. For repeat testing for ANA ,  
during the screening period , see Section 5.4.1 . 
[6]  Have a SLEDAI -2K score ≥6 at screening (Visit 1) and clinical SLEDAI -2K score ≥4 at 
randomizatio n (Visit 2) . 
[7]  Have active arthritis and/or active rash as defined by the SLEDAI -2K at screening and at 
randomization . 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 35 5.2. Exclusion Criteria  
Patients  will be excluded from the study if any one of the following criteria are met : 
Corticosteroid  use 
[8]  Are currently receiving oral corticosteroids at doses >20 mg per day of prednisone (or 
equivalent) or have adjusted the dosage of corticosteroids within 2 weeks before  
randomization  (Visit 2) . 
[9]  Have received topical corticosteroids, other than stable d oses of Class VI (mild, such as 
desonide) or Class VII (least potent, such as hydrocortisone), within 8 weeks before 
randomization  (Visit 2) . 
[10]  Have received parenteral (that is, intravenous  or intramuscular) corticosteroids within 12 
weeks before randomization (Visit 2)  or are expected to require parenteral corticosteroids 
during the study . 
Other prior or concomitant therapy  
[11]  Have started treatment with or adjusted the dosage of NSAIDs intended for treatment of 
signs and symptoms of SLE within  2 weeks before randomization (Visit 2) . 
[12]  Have started treatment with or adjusted the dosage of an antimalarial (such as 
hydroxychloroquine, chloroquine, or quinacrine) within 12 weeks before randomization 
(Visit 2) ; or have received more than a singl e antimalarial  within 12 weeks before 
randomization (Visit 2) . 
[13]  Have  started treatment with or adjusted the dosage of an immunosuppressant (such as 
methotrexate, azathioprine, mycophenolate mofetil, or mizoribine ,) within 12 weeks before 
randomization (Visit 2) ; or have received  more than a single  immunosuppressant  within 12 
weeks before randomization (Visit 2) . 
[14]  Have received  an oral calcineurin inhibitor , such as  cyclosporine, tacrolimus, sirolimus , or 
voclosporin , within 12 weeks before randomization (Visit 2) . 
[15]  Have received  an oral Janus kinase (JAK) inhibitor , including but not limited to baricitinib, 
tofacitinib , and upacitinib, within 12 weeks before randomization (Visit 2) . 
[16]  Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks before 
randomi zation (Visit 2) . 
[17]  Have received biologic  therapies  in the specified number of weeks before screening:  
[17a]  rituximab or ustekinumab  within 24 weeks before  randomization (Visit 2) , 
[17b]  other biologic therapies including, but not limited to , anticytokine  or receptor 
blocker  (etanercept, infliximab, certolizumab, adalimumab, golimumab, tocilizumab, 
anakinra, ixekizumab , secukinumab, belimumab , abatacept ) within 12 weeks before 
randomization (Visit 2) . 
[18]  Have received intravenous Ig within 2 4 weeks before randomization (Visit 2) . 
[19]  Have received plasmapheresis  within 12 weeks before randomization (Visit 2) . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 36 [20]  Have  received any live vaccine (that is, live attenuated) within 12 weeks of screening  
(Visit  1), or intend to receive a live vaccine during the study , or plan to receive such 
vaccine within 8 weeks of completing treatment in this study . 
[21]  Have received a Bacillus Calmette -Guerin (BCG) vaccination or treatment within 
12 months of screening  (Visit 1) or intend to have vaccination with BCG during the course 
of the study , or plan to receive su ch vaccination within 8 weeks of completing treatment in 
this study . 
[22]  Have participated within the last 30 days in a clinical study involving an investigational 
product . If the previous investigational product  has a long half -life, at least 5 half-lives or 
30 days (whichever is longer) should have passed  before the randomization visit (Visit 2) 
of Study  KFAJ . 
[23]  Have received treatment with aldesleukin or other IL -2–related treatment . 
Current or historical i nfections  
[24]  Have  a current or recent acute, active infection. For at least 30 days prior to screening  
(Visit  1) and up to the time of randomization  (Visit 2) , participants must have no symptoms 
or signs of confirmed or suspected infection , and must have completed any appropriate 
anti-infective treatment.  
Note : Participants with  an upper respiratory infection or a vaginal/oral candida infection 
being treated on ly symptomatically and not requir ing systemic anti-infectives may be 
considered for enrollment if other eligibility criteria are met . Other uncomplicated local 
infection s should be discussed with the sponsor’s medical monitor.  
[25]  Have  had, within 12 weeks before randomization  (Visit 2) , any of the following types of 
infection : 
○  Serious  (requiring hospitalization, and/or intravenous or equivalent oral antibiotic 
treatment) , 
○  Opportunistic (as defined in Winthrop at al. 2015) ,  
Note:  Herpes zoster is considered active and ongoing until all vesicles are dry and 
crusted  over, 
○  Chronic ( duration of symptoms, signs, and/or treatment of 6 weeks or longer) , 
○  Recurring (including, but not limited to, herpes simplex, herpes zoster, recurring 
cellulitis, chronic osteomyelitis).  
Note:  Participants with only recurrent, mild and uncomplicated orolabial and/or genital 
herpes may be considered for enrollment if discussed with the sponsor’s designated 
medical monitor and if other eligibility criteria are met . 
[26]  Have human immunodeficienc y virus (HIV) infection . 
[27]  Have a current infection with hepatitis B virus  (HBV DNA)  (that is, positive for hepatitis B 
surface antigen [HBsAg] and/or PCR positive for HBV DNA ). 
[28]  Have  a current infection with hepatitis C virus  (that is, positive for HCV RNA ). 
[29]  Have current or past history of active tuberculosis (TB)  (see Section 8.2.6 ). 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 37 [30]  Have or have had latent TB infection (LTBI) that has not been treated with a complete 
course of appropriate therapy as defined by the World Health Organization and/or the 
United States Centers for Disease Control and Prevention, unless such treatment is 
underway  (see Section 8.2.6 ). 
Other current or historical  medical  conditions  
[31]  Have  severe active lupus nephritis  defined clinically and/or by  urine protein/creatinine 
ratio >300  mg/mmol (as an estimate of approximate proteinuria >3  g/day) or active urinary 
sediment with red blood cell cast(s), or histological evidence of lupus nephritis  (Class III, 
IV, V, or VI according to the International Society of Nephrology classification criteria) 
within 12 weeks before randomization (Visit 2) . 
Note:  For laboratory retesting related to lupus nephritis , see Section 5.4.1 . 
[32]  Have active severe central nervous system lupus including aseptic meningitis, cerebral 
vasculitis, demyelinating syndrome, myelopathy, ac ute confusional state, psychosis, acute 
inflammatory demyelinating polyradiculoneuropathy, cranial neuropathy, plexopathy, 
status epilepticus, or cerebellar ataxia  within 24 weeks before randomization (Visit 2) . 
[33]  Have active fibromyalgia that, in the investigator’s opinion, would make it difficult to 
appropriately assess SLE activity for the purposes of this study . 
[34]  Have  been treated for or had an active occurrence of a systemic inflammatory condition 
other than SLE, such as, but not limited to, rheumatoid arthritis, juvenile chronic arthritis, 
spondyloarthropathy, Crohn’s disease, ulcerative colitis, or psoriatic arthrit is in the 
12 weeks before randomization (Visit 2) . 
Note:  Participants with secondary Sjögren’s syndrome are not excluded . 
[35]  Have  experienced a thrombotic event within 24 weeks before randomization or are on 
anticoagulants and in the opinion of the investigator are not well -controlled regarding 
management of hypercoagulable risk . 
[36]  Have experienced any of the following within 12  months  before screening: myocardial 
infarction, unstable ischemic heart disease, stroke, or New York Heart Association Stage 
IV heart failure . 
[37]  Have a history of clinically significant or uncontrolled cardiovascular disease (for example, 
hypertension , angina, congestive heart failure); endocrine disorder (for example, diabetes, 
thyroid dysfunction); or respiratory, hepatic, renal, gastrointestinal, hematologic, or 
neuropsychiatric disorder ; or any other serious and/or unstable illness that in the opinion of 
the investigator, could constitute an unacceptable risk to the participant when taking an 
investigational product or could interfere with the interpretation of  study  data. 
[38]  Are, in th e judgment of the investigator, actively suicidal and therefore deemed to be at 
significant risk for suicide.  
[39]  Have answered “yes” to either Question 4 or Question 5 on the “Suicidal Ideation” portion 
of the Columbia -Suicide Severity Rating Scale (C -SSRS) or 
have answered “yes” to any of the suicide -related behaviors on the “suicidal behavior” 
portion of the C -SSRS,  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 38 and the ideation or behavior occurred within 4 weeks prior to randomization (Visit  2). 
[40]  Have  a history of lymphoproliferative disease; or have signs or symptoms suggestive of 
possible lymphoproliferative disease, including lymphadenopathy or splenomegaly (other 
than primarily because of SLE); or have active primary or recurrent malignant disease;  or 
have been in remission from clinically significant malignancy for <5 years . 
Exceptions:  
○  Participants with cervical carcinoma in situ that has been resected with no evidence of 
recurrence or metastatic disease for at least 3 years may participate in  the study if other 
study entry are met.  
○  Participants with basal cell or squamous epithelial skin cancers that have been 
completely resected with no evidence of rec urrence for at least 3  years may participate 
in the study if other study entry criteria a re met . 
[41]  Have had any major surgery within 12 weeks before randomization (Visit 2)  or will require 
major surgery during the study that, in the opinion of the investigator in consultation with 
Lilly or its designee, would pose an unacceptable risk to the participant . 
[42]  Have a known allergy to the investigational intervention or any o f its excipients, clinically 
significant multiple or severe drug allergies, intolerance to topical corticosteroids, or 
history of severe post -treatment hypersensitivity reactions, including, but not limited to, 
erythema multiforme major, linear immunoglobu lin A (IgA) dermatosis, toxic epidermal 
necrolysis, or exfoliative dermatitis . 
Diagnostic assessments  or abnormal laboratory values  
[43]  Have any of the following specific abnormalities on screening laboratory tests:  
●  alanine  aminotransferase (ALT) or aspartate aminotransferase  (AST)  >2 times upper 
limit of normal ( ULN ) 
●  total bilirubin  level (TBL)  ≥1.5 times ULN  
●  hemoglobin <8.5 g/dL (<85.0 g/L)  
●  total white blood cell count (WBC) <2500 cells/µL (<2.50 × 10 3/µL or <2.50  GI/L)  
●  eosinophilia ( absolute eosinophil count >3000 cells/µL (>3.0 × 10 3/µL or >3.0  GI/L)  
●  neutropenia – absolute neutrophil count  (ANC)  <1000 cells/µL  
(<1.00  × 103/µL or <1.00  GI/L)  
●  lymphopenia  – absolute lymphocyte count  (ALC)  <500 cells  /µL  
(<0.50 × 10 3/µL or <0.50  GI/L)  
●  thrombocytopenia  – platelets <50,000 cells/µL (<50 × 10 3/µL or <50  GI/L)  
●  estimated glomerular filtration rate  (eGFR)  (Modification of Diet in Renal Disease  
[MDRD] ) <50  mL/min/1.73 m 2 (FDA 2010) . 
Note:  For repeat testing of screening laboratory tests, see Section 5.4.1 . 
[44]  Have known hypogammaglobulinemia or a screening immunoglobulin G (IgG) 
level <565  mg/dL (<5.65  g/L). 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 39 [45]  Have other abnormal laboratory values at screening that, in the opinion of the investigator, 
indicate  unacceptable risk for the participant’s safety in the study . 
[46]  Have  screening electrocardiogram (ECG) abnormalities that, in the opinion of the 
investigator, are clinically significant and indicate an unacceptable risk for the participant’s  
safety in the study .  
Previous or c oncurrent clinical study experience  
[47]  Have previously been randomized in this study or have received LY3471851 in any 
previous study . 
[48]  Are currently enrolled in any other clinical study involving an investigational product or 
any other type of medical research judged not to be scientifically o r medically compatible 
with this study . 
Other exclusions  
[49]  Are largely or wholly incapacitated , permitting little or no self -care, such as being 
bedridden or confined to wheelchair . 
[50]  Have donated more than a single unit of blood within 4 weeks before randomization 
(Visit  2)  or intend to donate blood during the course of the study . 
[51]  Have a  history of chronic alcohol abuse, intravenous (IV) drug abuse, or other illicit drug 
abuse within 1 year before screening . 
Note:  Marijuana is considered an illicit drug for the purposes of this study, regardless of 
local laws. Cannabidiol (CBD) products m ay be used during the study if they are derived 
exclusively from hemp. Participants who use hemp -based CBD products must be on a 
stable dose for at least 10 days prior to randomization , and participants must remain on that 
stable dose during the study.  
[52]  Are unable or unwilling to make themselves available for the required number of study 
visits or unwilling to follow  the restrictions  and procedures  of the study . 
[53]  Are women who intend to become pregnant or breastfeed at any time in the study . 
[54]  Are investigat ive site personnel directly affiliated with this study and/or their immediate 
families. Immediate family is defined as a spouse, parent, child, or sibling, whe ther 
biological or legally adopted.  
[55]  Are  employees of Eli Lilly and Company (Lilly) or are employees of a third -party 
organization involved in the study , which requires exclusion of their employees.  
5.3. Lifestyle Considerations  
Not applicable.  
5.4. Screen Failures  
Screen failure  is defined as participant s who consent to participate in the clinical study  but are 
not subsequently randomly assigned to study intervention . A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participant s to meet t he 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 40 Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, 
screen failure details, eligibility criteria, and any serious adverse event  (SAE ). 
5.4.1.  Allowed Retesting of Screening Investigations  
Repeat ing laboratory tests during the screening period does not constitute rescreening.  
In particular, t he following laboratory tests may be repeated once  during the screening period to 
determine a participant’s eligibility for randomization:  
●  tests for ANA ,  
●  tests related to  lupus nephritis , and  
●  clinical chemistry, hematology,  calculation of  estimated glomerula r filtration rate . 
See Section 8.2.6  for retesting related to TB . 
5.4.2.  Rescreening of Individual s Who Failed Screening  
Informed consent for rescreenings  
Individuals who are to be rescreened must first sign a new ICF (Appendix 10.1, Section 10.1.3 ). 
Such individuals will be assigned a new participant number.  
Rescreening after failure to meet study entry  criteria  
An individual who does not meet the criteria for participation in this study  may be rescreened 
one time  if the reason for the screen failure has resolved and if the  sponsor has approved the 
rescreening . The interval between the failure  to meet study entry criteria and the start of 
rescreening  should be at least 4  weeks . 
Rescreening  for administrative reasons  
An individual may be rescreened one time  for an admin istrative reason, including, for example, 
but not limited to, falling out of the screening window because of scheduling conflicts. The 
sponsor does not need to approve rescreening for an administrative reason . The rescreening can 
start immediately after th e administrative reason has resolved.  
Procedure s not required to be repeated during rescreening  
Individuals in rescreening  who have already completed the protocol -required  screening 
chest  x-ray (CXR)  or TB tests  are not required to repeat these procedures if they were performed 
within 90 days before the date of signing the rescreening ICF. However, these procedures can be 
repeated at the discretion of the investigator.  
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 42 Investigators should consult the information provided in the Pharmacy Manual or the label for 
specific preparation and administration information, including warnings, precautions, 
contraindications, adverse reactions, and dose modifications . 
Preparation  
The IPs must be prepared by an unblinded pharmacist (or other unblinded qualified individual) 
who is not involved in any other study -related procedures . 
Handling and storage  
Follow  the storage and handling instructions for the IP as noted in  the IP packaging . The 
handling and storage information for the administered product is located in the Pharmacy 
Manual.  
Site responsibilities and accountability  
The following are responsibilities of the investigator or his or her designee:  
●  The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and that any discrepancies are 
reported and resolved before use of the study intervention.  
●  Only  participants enrolled in the study may receive study intervention , and only 
authorized site staff may supply or administer study intervention. All study intervention 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automate d) area in accordance with the labeled storage conditions with access limited to 
the investigator and authorized site staff.  
●  The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention a ccountability, reconciliation, and record maintenance 
(that is , receipt, reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused study interventions are 
provided in the Pharmacy Manual . 
The inves tigator or designee is  also responsible for  
•  explaining the correct use of the study interventions  
•  verifying that instructions are followed properly  
•  maintaining accurate records of IP dispensing and collection, and  
•  returning all unused medicatio n to Lilly or its designee at the end of the study . 
Note:  In some cases, sites may destroy the material if, during the investigative site 
selection, the evaluator has verified and documented that the site has appropriate 
facilities and written procedures t o dispose of clinical materials . 
6.3. Measures to Minimize Bias: Randomization and Blinding  
Blinding will be maintained throughout the conduct of the study as described in the separate 
Unblinding Plan.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 43 Method of treatment assignment  
Assignment to treatment groups will be determined by a computer -generated random sequence 
using an interactive web -response system (IWRS).  
Unblinded pharmacist  
Investigators and all individuals invo lved in administering the blinded tr eatment or performing 
assessments wi ll remain blinded to each participant’s assigned study intervention throughout the 
course of the study. To maintain this blind, an otherwise uninvolved party (unblinded pharmacist 
or other unblinded qualified individual) will be responsible for the prepara tion and dispensation 
of all study intervention. Blinded site personnel will administer the study intervention to the 
participant.  
Independent assessor for injection site reactions  
At every visit following the first dose and p rior to any  blinded  study activity, an independent 
Injection Site Reaction (ISR) assessor  who is not involve d with other study procedures will 
evaluate  each participant  for the presence of ISRs.  If the participant presents with symptoms of 
an ISR (see Section 8.2.11 ), the ISR assessor will examine the impacted areas and record the 
information in the electronic case report form ( eCRF ). 
Whether an ISR is present or not, t he ISR assessor will use a bandage (or similar material) to 
cover  the anatomical area where the participant received his or her last dose . The purpose of 
covering this area is to minimize bias  when blinded study personnel conduct other study 
assessments , given the known frequency  of ISRs  with the molecule . 
Emergency unblinding  
Emergency unblinding for adverse events  may be performed through the IWRS . This option may 
be used ONLY if the participant’s well -being requires knowledge of the participant’s treatme nt 
assignment. All actions resulting in an unblinding event are recorded and reported by the IWRS . 
If a participant’s study treatment assignment is unblinded  to blinded  site personnel performing 
assessments , including the investigator , or to the participan t, the participant must be discontinued 
from study  drug, unless the investigator obtains specific approval from the sponsor’s medical 
monitor for the participant to continue (Section 7.1.1 ). 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a participants’ intervention assignment is warranted. Participant safety must always be the first 
consideration in making such a determination. If the in vestigator decides that unblinding is 
warranted, it is the responsibility of the investigator to promptly document the decision and 
rationale and notify the sponsor  as soon as possible . 
In cases where there are ethical reasons to have the  participant remain in the study, the 
investigator must obtain specific approval from the sponsor ’s clinical research physician  for the  
participant to continue in the study.  
6.4. Study Intervention Compliance  
Participants  will receive study intervention directly  from the investigator or designee  at the study 
site, under medical supervision. The date and time of each dose administered in the clinic will be 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 44 recorded in the source documents and recorded in the eCRF.  Deviations from the prescribed 
dosage regimen shou ld be recorded in the eCRF . 
6.5. Concomitant Therapy  
Participants will be instructed to consult the investigator or other appropriate study site personnel 
before taking any new medications or supplements during the study . The sponsor’s medical 
monitor should be contacted if there are any questions . 
Recording of concomitant therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving at the time of enrollme nt or receives 
during the study must be recorded along with  
•  reason for use ,  
•  route of administration, and 
•  dates of administration , including start and end dates . 
For concomitant therap ies of special interest , dosage information will also be collec ted as well as 
reason for use and route and dates of administration.  
Allowed concomitant  therapy  
Participants will maintain their usual medication regimen for SLE and for any other diseases 
throughout the study unless  specifically excluded in the protocol  (Section 5.2). Doses must be 
stable prior to randomization , as stated in the exclusion criteria . Permitted  concomitant 
background standard -of-care medications for SLE can include any combination of  these : 
•  NSAIDs,  
•  a single antimalarial (such as hydroxychloroquine , chloroquine, or quinacrine ),  
•  a single oral immunosuppressant from the following list: methotrexate, azathioprine, 
mycophenolate  mofetil, or mizoribine ,  
•  a single corticosteroid.  
Dose adjustment for NSAIDs, antimalarials, and immunosuppressants  
Doses of NSAIDs intended for treatment of signs and symptoms of SLE, antimalarials, and 
immunosuppressants should not be adjusted during the study’s double -blind treatment pe riod. 
Participants who require initiation or increase in dosage of NSAIDs for treatment of signs and 
symptoms of SLE, or of antimalarials, or  of immunosuppressants after randomization may 
remain in the study and continue receiving study drug . 
Dose adjustme nt for corticosteroid s 
See Section 6.5.1 . 
6.5.1.  Corticosteroid Management Program  
Key elements of the corticosteroid management program of this study include  the following:  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 45 ●  Participants  are restricted to prednisone ≤20 mg  per day  (or equivalent) at randomization 
(Visit 2) , having been on stable dose s for at least  2 weeks  prior to randomization . 
●  Following randomization , the dose of prednisone (or equivalent)  should not be increased  
above the participant’s background  level.  
●  Participants on >10 mg per day are required to taper their dose to ≤10 mg per day by 
Week 12  to be considered responders . 
●  The corticosteroid doses  should not be changed  after Week 18.  
●  Participants  with intolerable or exacerbating disease are allowed access to standar d-of- 
care therapy , including increasing the  dose of prednisone (or equivalent) . Such 
participants  are allowed to remain  in the study and continue receiving study drug, but they 
will be considered nonresponders for the efficacy analyses from the time of the 
medication change onward . 
Guidance on c orticosteroid tapering  
The following guidance on corticosteroid tapering is provided for participants  taking >10 mg 
prednisone (or equivalent ) at baseline.  
●  Steroid tapering should begin no sooner than 4  weeks after randomization.  
●  Tapering should include a stepwise reduction in  2.5 mg/d to 5 mg/d increments, with each 
step reduction occurring at 2 -week intervals. Thus, the stepwise reduction will occur in 
intervals that are consistent with the visit schedule.  
●  Participants who do not tolerate a reduction can increase the dose up to, but not exceeding, 
the dose at randomization . 
Under this schedule, a participant  on the  highest allowed dose of 20 mg per day  at randomization 
would tape r his or her  steroid dose in 2.5 mg per day  increments at 2 -week intervals to achieve 
the target of ≤10 mg per day in time for the assessments at  Week 12 . 
Participants who are taking ≤10 mg prednisone (or equivalent ) at baseline may have their dose 
tapered at the discretion of the investigator. Howeve r, the corticosteroid doses should not be 
changed after Week 18 . 
These recommendations recognize that there is variability in how corticoster oids are 
administered. The intent is to allow  investigators flexibility in how corticosteroids are tapered for 
individual participants , provided that the participants  reach the goal of ≤10 mg per day in time 
for the assessments at W eek 12 . 
Concomitant  therapy after permanent discontinuation of study dru g 
Standar d-of-care therapy can be resumed after the participant is permanent ly discontinued  from 
study drug.  
6.6. Dose Modification  
Modification of the dose of the study intervention is not permitted in this study . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 46 6.7. Intervention  after the End of the Study  
LY3471851  will not b e available to participants following completion of the study . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 47 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
In rare instances, it may be necessary for a participant to permanently discontinue study drug.  
These sections describe reasons for  a participant’s  
•  permanent or temporary discontinuation of study drug  (Section 7.1), or 
•  discontinuation (withdrawal) from the study  (Section 7.2). 
Discontinuation of specific sites or the trial as a whole (“stopping rules”) are  handled as part of 
regulatory, ethical, and trial oversight considerations in Appendix 10.1, Section 10.1.9 . 
7.1. Discontinuation of Study Intervention  
Study drug may be permanently discontinued or temporarily withheld during the study . 
Participants who permanently discontinue study drug early will undergo early termination 
procedures, which include  
• an early termination visit ( ETV )  
   AND , 
• post-treatment follow -up visits , as shown in the SOA . 
7.1.1.  Criteria for Permanent Discontinuation of Study Drug  
Data collection and  safety  follow -up when study drug is permanently discontinued  
If study drug is permanently discontinued, the participant will remain in the study to have an 
ETV and post -treatment follow -up visits, as shown in the SoA (Section 1.3). 
See the SoA for data to be collected at the time of discontinuation and follow -up and for any 
further evaluations that need to be completed . Safety follow -up is as outlined in the SoA (Section 
1.3), Section 8.2 (“Safety Assessments),  
 of the protocol.  
The presence or absence of a clinica lly significan t ISR will not unblind  participants and is 
therefore not a protocol deviation .  
Criteria for permanent discontinuation of study drug  
Possible reasons for permanent discontinuation of study drug include, but are not limited to , the 
following:  
Participant decision  
●  The participant requests to discontinue the study drug . 
Pregnancy  
●  The participant becomes pregnant during the study (see Section 8.2.5.1 ). 
Safety considerations  
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 48 ●  The participant develops  any of the following conditions during the study : 
−  malignancy (except for successfully treated basal or squamous cell skin carcinoma)  
−  HIV/acquired immune deficiency syndrome (AIDS) infection  
−  active TB  infection  or untreated L TBI (Section  7.1.2 ; Section 8.2.6 ) 
−  HCV RNA positive  (Section  8.2.8 ) 
−  HBV DNA positive  and clinical assessment consistent with HBV reactivation  
Note:  The HBV DNA result is to be confirmed if initial positive test result is 
positive but below the level of quantification (Section  7.1.2 ; Section  8.2.7 ). The 
participant is to be referred to, evaluated, and managed by a specialist physi cian 
with expertise in evaluation and management of viral hepatitis prior to 
discontinuation of any immunomodulatory and/or immunosuppressive therapy, 
including study drug. Timing of discontinuation from study drug relative to the 
initiation of any antiviral treatment for hepatitis is to be based on the 
recommendation of the consulting specialist physician, in conjunction with the 
investigator, and aligned with medical guidelines and standard of care.  
●  The partici pant answered yes" to Question 4 or Question 5 on the "Suicidal Ideation" 
portion of the C -SSRS, or answered "yes" to any of the suicide -related behaviors on the 
Suicidal Behavior portion of the C -SSRS.  
Note : A psychiatrist or appropriately trained profess ional may assist in the decision 
to discontinue the participant.  
●  The investigator , after consultation with the sponsor’s designated medical monitor, 
determines that a systemic hypersensitivity reaction has occurred and is related to study 
drug administr ation . 
●  The participant  has any of the following results on 2 consecutive samples taken at least 
48 hours , but no more than 1 week,  apart . 
−  Total WBC <1000 cells/ L 
−  ANC <500 cells/ L 
−  ALC <200 cells/ L 
−  Hemoglobin <6.5 g/dL  
●  The  participant develops CRS. In consultation with the Lilly medical monitor, if an 
adverse event is deemed possibly or probably due to CRS based on the details and 
severity of clinical signs and symptoms, time course of symptom onset relative to 
study drug a dministration, and if possible, a cytokine panel from a blood sample 
obtained at the time of the event , the participant will be discontinued from study 
treatment, and will continue safety follow -up. 
●  The participant develops hyper eosinophilia . 
○  Partici pants with absolute eosinophil counts >1500 cells/µL and signs and/or 
symptoms of target organ involvement that is not consistent with lupus and/or  with the 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 49 participant’s lupus and medical history will be discontinued from study drug in 
consultation with the medical monitor. Participants  will undergo appropriate medical 
evaluation , which  should take into account the pa rticipant ’s known lupus and past 
medical history  according to the participant’s history and medical records, including  
previous imaging, biopsies  and laboratory findings. Evaluation of target organ 
involvement will involve additional  diagnostic tests as appropriate, including 
laboratory tests, imaging (for example,  echocardiogram, CXR , computed tomography 
[CT] scan) and b iopsies . New onset cardiac, pulmonary, and skin findings in the 
setting of peripheral eosinophilia will  be considered as target organ involvement, 
unless attributable to other causes.  
○  Asymptomatic participants  with an  absolute  eosinophil count >5000 cel ls/µL should 
have a repeat measurement to confirm the count . If the count is confirmed, the 
participant  will be permanently discontinued from study drug  and undergo appropriate 
medical evaluation . 
●  The participant has an adverse event  or a SAE  or a clini cally significant change in a 
labor atory value that, in the opinion of the investigator, merits the discontinuation of the 
study drug and appropriate measures being taken.  
Hepatic event or liver test abnormality  
●  Participants  who are discontinued from study drug because of a hepatic event or liver test 
abnormality should have additional hepatic safety data collected via the hepatic eCRF 
packet. Discontinuation of study drug because of abnormal liver tests should be 
considered by the investigator when a participant meets one of the following conditions 
after consultation with the sponsor’s designated medical monitor (see Section 8.2.9 ). 
−  ALT or AST >8 times ULN  
−  ALT or AST >5 times ULN  sustained for more than 2 weeks  
−  ALT  or AST >3 times ULN and TBL >2 times ULN or international normalized ratio 
(INR) >1.5  
−  ALT or AST >3 times ULN  with the appearance of fatigue, nausea, vomiting, right 
upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
−  alkaline phosphatase ( ALP ) >3 times ULN  
−  ALP >2.5 times ULN and TBL >2 times ULN, or  
−  ALP  >2.5 times ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).  
Other reasons  
●  Unblinding : If an investigator, blinded site personnel who are performing assessments, or 
participant is unblinded  to a participant’s treatment assignment , the participant must be 
discontinued from the study drug and continue to post -treatment follow -up. In cases where 
there are ethical reasons to have the participant continue on study drug, the investigator 
must obtain specific approval from the sponsor’s designated medical monitor  for the 
participant  to continue.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 50 7.1.2.  Criteria for Temporary Interruption (Withholding) of Study Drug  
7.1.2.1.  Infection -Related  Criteria  for Temporary Withholding  of Study Drug  
Temporary withholding  of study drug is required for the development of any of the following 
infection -related criteria during the study:  
●  Serious or opportunistic infections, as defined in Exclusion Criteria (Section 5.2). Study 
drug is to be withheld until resolution of all acute clinical signs and symptoms, and 
completion of all appropriate anti -infective treatment (exception for LTBI , noted below).  
●  Participants diagnosed with LTBI during the study are to be permanently discontinued 
from study drug unless the participant is a candidate for LTBI treatment, and is treated for 
LTBI as follows:  
−  Study drug is temporarily withheld for at least the first 4 weeks of LTBI treatment.  
−  After receiving at least 4 weeks of appropriate LTBI therapy (as per World Health  
Organization and/or the United States Centers for Disease Control guidelines), if there 
is no evidence of hepatotoxicity (ALT/AST must remain ≤2 times ULN) or other 
treatment intolerance, study drug may be resumed.  
−  The participant must complete appropr iate LTBI therapy to remain eligible to receive 
study drug. 
●  HBV DNA results that are reported as positive, or as detecting HBV DNA, but HBV DNA 
is below the level of quantification. The sponsor’s d esignated medical monitor should be 
contacted regarding study status of the participant . HBV DNA testing is to be repeated as 
soon as is feasible. If HBV DNA is confirmed as positive, the participant must be 
permanently discontinued from study drug (Section 7.1). 
7.1.2.2.  Other Criteria for Temporary Withholding of Study Drug  
In some circumstances, it may be advisable  to temporarily interrupt study drug  as a result of 
adverse even ts or abnormal laboratory va lues that have an unclear relationship to study drug . 
Except in an emergency, t he investigator should consult with sponsor’s designated medical 
monitor  whenever possible  before temporarily withholding study drug for reasons not specified 
in Section 7.1.2.1  above.  
7.2. Participant Discontinuation/ Withdrawal from the Study  
Participant discontinuation (withdrawal from the study) is expected to be uncommon.  
A participant  will withdraw from the study  in the following circumstances : 
●  at any time at his or her own request, or at the request of his or her designee (for example, 
parents or legal guardian)  
●  at the discretion of the investigator for safety, behavioral, compliance, or administrative 
reasons  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 51 ●  if the participant enrolls in a ny other clinical study involving an investigational medicinal 
product or enrollment in any other type of medical research judged not to be scientifically 
or medically compatible with this study  
●  if the participant, for any reason, requires treatment wit h another therapeutic agent that has 
been demonstrated to be effective for treatment of the study indication. In this case, 
discontinuation from the study occurs prior to introduction of the new agent.  
Data collection and follow -up for participants who dis continue the study  
At the time of discontinuing from the study, an ETV should be conducted, if possible, as shown 
in the SoA  (Section 1.3). See the SoA for data to be collected at the time of study discontinuation 
and follow -up and for any further evaluations that need to be completed.  The participant will be 
permanently discon tinued both from the study drug and from the study.  
No follow -up procedures will be performed for a participant who withdraws informed consent 
unless he or she has explicitly provided permission and consent.  
Withdrawal of consent for disclosure  
If the participant  withdraws consent  for disclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent . If a participant  
withdraws from the study, he  or she may request destruction of any samples taken and not tested , 
and the investigator must document this in the site study records . 
7.2.1.  Discontinua tion of Inadvertently Enrolled Participants  
If the sponsor or investigator identif ies a participant  who did not meet enrollment criteria and 
was ina dvertently enrolled, then the participant  should be discontinued from study treatment 
unless there are extenuating circumstances that make it medically necessary for the participant  to 
continue on study treatment. If the investigator and the sponsor ’s clinical res earch physician 
agree that it is medically appropriate to continue, the investigator must obtain documented 
approval from the sponsor ’s clinical research physician  to allow the inadvertently enrolled 
participant to continue in the study with or  without treatment with investigational medicinal 
product.  Safety follow -up is as outlined in the SoA (Section 1.3), Section 8.2 (“Safety 
Assessments), and Section 8.3 (“Adverse Events and Serious Adverse Events”) of the protocol . 
7.3. Lost to Follow  up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  Site personnel are expected to 
make diligent attempts to contact participants who fail to return for a scheduled visit or were 
otherwise unable to be followed up by the site.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 52 8. Study Assessments and Procedures  
Study procedures and their timing are summarized in t he SoA  (Section 1.3). Protocol  waiver s or 
exemptions are not allowed.  
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.  
8.1. Efficacy Assessments  
Efficacy and patient -reported outcome assessments are described in Appendix 10.7. The primary 
and secondary efficacy endpoints are described  in the following subsections . 
The s elf-reported questionnaires will be administered in countries where the questionnaires have 
been translated into the native language of the r egion and linguistically validated. Any outcome 
measures that are participants’  self-assessments should be completed before  any clinical  
examinations  are performed . 
All patient -reported and clinician -reported efficacy assessments will be captured on an electronic 
tablet collected at site visits.  
8.1.1.  Primary Efficacy Outcome Measure: SLEDAI -4 
The primary efficacy  endpoint is the proportion of participants who achieve a SLEDAI -4 
response at Week  24. A SLEDAI -4 response is defined as a ≥4 -point reduction in Sys temic 
Lupus Erythematosus Disease Activity Index 2000 (SLEDAI -2K) score from baseline. To be 
considered a SLEDAI -4 responder, participants must complete the 24 -week treatment period and 
comply with concomitant medication rules  (Section 9.4.1 ). Section 4.2 provides the rationale for 
the selection of SLEDAI -4 as the primary efficacy measure.  
8.1.2.  Secondary Efficacy Outcome Measures  
8.1.2.1.  British Isles Lupus Assessment Group  (BILAG )-based Composite Lupus 
Assessment (BICLA)  
The BILAG -based Composite Lupus Assessment  (BICLA)  is a composite index  used to assess 
disease activity in SLE. A BICLA response is defined as  follows:  
●  Reduction of all baseline BILAG -2004 A to B or C or D; and baseline BILAG -2004 B to 
C or D; and no BILAG -2004 worsening in other organ systems, as defined by ≥1 new 
BILAG -2004 A or ≥2 new BILAG -2004 B  
●  No worsening from baseline in SLEDAI -2K, where worsening is defined as any increase 
from baseline in SLEDAI -2K 
●  No worsening  from baseline in participants ’ lupus disease activity, where worsening is 
defined by an increase ≥0.30 points on a 3 -point PGA visual analogue scale  (VAS)  
●  No permanent discontinuation of investigational product , and  
●  No use of restricted medications beyond the protocol -allowed threshold before assessment . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 53 8.1.2.2.  Systemic Lupus Erythematosus Responder Index -4 (SRI-4) 
The SRI-4 is a composite index  used to assess disease activity in SLE. The SLEDAI -2K 
component is used to capture clinically meaningful improvement in disease activity, while the 
BILAG and PGA  of Disease Activity components ensure that the improvement in overall disease 
is not accompan ied by disease worsening in other organ systems. A SRI-4 response is defined as  
follows:  
●  Reduction of ≥4 points from baseline in SLEDAI -2K score  
●  No new BILAG -2004 A or no more than 1 new BILAG  -2004 B disease activity score , 
and 
●  No worsening (defi ned as an increase of ≥0.3 points [10 mm] from baseline) in PGA  of 
Disease Activity . 
Participants must complete 24 weeks of the  study and comply with concomitant medication rules 
to be considered a responder for the SRI -4 analysis  (Section 9.4.1 ). 
8.1.2.3.  Lupus Low Disease Activity State  (LLDAS ) 
An LLDAS response  is defined as a low level of disease activity attained with or without use of 
low-dose steroids and/or tolerated standard maintenance doses of standard -of-care 
immunosuppressant medications (Franklyn et al. 2016) . 
8.2. Safety Assessments  
Visits and order of safety assessments  
Safety assessments occur at visits specified in the SoA (Section 1.3). If multiple safety 
assessments are scheduled for the same visit, the preferred order of completion is  
1)  ECG and then vital signs , 
2)  other safety assessments, including physical examinations and  nonleading (spontaneous)  
adverse event  collection , followed by C-SSRS  (Section  8.3.1.1 ), and finally  
4) blood sample collection for clinical laborator y,  
 
Data collection and reporting  
The adverse event  data collection and reporting requirements are described in Section 8.3 and 
Appendix  10.3.  
 
Any clinically significant findings that result in a diagnosis and that occur after the participant 
receives the first dose of study drug should be reported to Lilly or its designee as an adverse 
event  via eCRF.  
Safety monitoring  
The principle investigator  will monitor the safety data throughout the study and should discuss 
immediate s afety concerns with the sponsor immediately upon occurrence or awareness to 
determine whether the participant should continue or discontinue the study drug. 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 54 The sponsor will moni tor the safety data, including adverse events  and SAE , discontinuations, 
vital signs, and clinical laboratory results  by means of  blinded reviews  performed at least 
quarterly and by other appropriate methods. These methods include review s by a functionally  
independent safety physician and/or clinical research scientist who regularly reviews SAE 
reports in real time and across studies , and who reviews applicable clinical safety and 
epidemiological publications from the literature . If this safety monitoring uncovers an issue that 
needs to be addressed by unblinding at the individual or group level, additional analyses of the 
safety data can be performed by the sponsor’s independent internal safety review committee  
(Section  10.1.5). 
Appropriateness of safety assessments  
The safety assessments  used in this study are routine elements of clinical health assessment and 
Phase  2 drug development . 
8.2.1.  Vital Signs  
Vital signs (blood pressu re, pulse rate, body temperature) will be measured  as specified in the 
SoA (Section 1.3) and as clinically indicated . Additional vital signs may be measured during the 
study visit s if warranted , as determined  by the investigator . 
Blood pressure and pulse rate should be measured after the participant has been sitting for at 
least 5 minutes.  
Unscheduled orthostatic vital signs should be assessed, if possible, during any adverse event  of 
dizziness or posture -induced symptoms. If the participant feels unable to stand, sitting or supi ne 
vital signs will be recorded.  
8.2.2.  Physical Examinations  
A complete physical examinations and symptom -directed physical examinations will be 
conducted at the visits specified in the SoA (Section 1.3). Symptom -directed physical 
examination s may also be conducted  at other visits, as determined  by the investigator , if a 
participant presents with complaints . 
At screening and at approximately every third month thereafter, the specified physical 
examination , whether complete or symptom -directed, should include an assessment of TB risk 
factors and symptoms or signs of TB, including  an assessment of peripheral lymph nodes ( see 
Section 8.2.6 ). 
The complete physical examination  should  include the following regions  and body systems : 
●  general appearance  
●  skin  (other than the area covered by the bandage to assess ISRs)  
●  head, ears, eyes, nose, throat  
●  lymph nodes  
●  cardiovascular  
●  respiratory  
●  abdominal  
●  genitourinary (only as clinically indicated)  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 55 ●  extremities (tender/swollen joint counts to be do cumented separately) , and  
●  neurologic . 
Height  (without shoes)  and weight will also be measured and recorded  as specified in the SoA  
(Section 1.3). 
8.2.3.  Electrocardiograms  
For each participant, 12 -lead ECGs will be collected as specified in the SoA (Section 1.3). The 
ECGs  should be recorded before collecting any blood for safety or PK tests. Participants must be 
supine for approximately 5 to 10 minutes before ECG collection and remain supine but awa ke 
during ECG collection.  
Electrocardiograms may be obtained at additional times, when deemed clinically necessary. 
Collection of additional ECGs at a particular time point is allowed to ensure high quality records . 
Electrocardiograms will be interpreted b y a qualified physician (the investigator or qualified 
designee) at the study site as soon after the time of ECG collection as possible, and ideally while 
the participant is still present, to determine whether the participant meets the study entry criteria  
and for immediate participant management, should any clinically relevant findings be identified . 
If a clinically significant finding is identified (including, but not limited to changes from baseline 
in QT/ QTc interval from baseline) after enrollment, the  investigator or qualified designee, in 
conjunction with the sponsor’s medical monitor, will determine whether the participant can 
continue in the study and if any change in participant management is needed.  
The investigator or qualified designee must docu ment his or her review of the ECG printed at 
collection.  Any new clinically relevant finding will be reported as an AE.  
8.2.4.  Chest Radiography  
A posterior –anterior (PA) CXR, interpreted and reported by a radiologist or pulmonologist, will 
be obtained as specified in the SoA (Section 1.3). 
A lateral CXR can also be obtained if, in the opinion of the investigator, a lateral view is 
indicated.  
Note:  Participants do not need to have a CXR at screening if, based on the judgment of 
the investigator, both of the following two conditions are met:  
•  the CXR was performed within 3 months before initial screening, and  
•  documentation of the CXR, read by a qualified radiologist or pulmonologist, is 
sufficient for TB evaluation according to local standard of care.  
For each participant, the CXR films or  images or a radiology report must be available to the 
investigator for review  before the participant is randomized . Certain findings from CXR may be 
consistent with a condition that excludes a participant from the study; see Section 5.2. 
Note:  Results of a chest CT scan or other imaging study similar to a CXR may be 
substituted in place of the CXR as described above, in consultation with the sponsor’s 
medical monitor.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 56 8.2.5.  Laborat ory Tests  
Appendix 10.2 lists the clinical laboratory tests to be performed , and the SoA (Section 1.3) 
specifies the study visits at which samples are routinely collected for clinical laboratory tests . 
Samples for laboratory testing will be obtained in the event of anaphylaxis or generalized 
urticaria , as de scribed in Section 8.3.6.1  and Appendix 10.2. Additional tests may be performed 
at any time during the study as deemed  necessary by the investigator or as required by local 
regulations.  
All protocol -required laboratory assessments, as defined in Appendix 10.2, must be conducted in 
accordance with the laboratory manual and the SoA (Section 1.3). 
If laboratory values from non -protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in p articipant management or are considered 
clinically significant by the investigator (for example, SAE or adverse event or dose 
modification), then the results must be recorded in the eCRF.  
Reviewing and recording test results  
The investigator must review th e laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the adverse event  section of the eCRF. 
The laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by the investigator to be more severe than expected for t he participant's condition.  
Repeat testing after clinically significant abnormal findings  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or within 8 weeks  after the last dose of study interve ntion should be repeated until 
the values return to normal or baseline or are no longer considered clinically significant by the 
investigator or the medical monitor.  If such values do not return to normal/baseline within a 
period of time judged reasonable by the investigator, the etiology should be identified and the 
sponsor notified.  
Blinding of laboratory test results  
Laboratory results that could unblind the study will not be reported to investigative sites or other 
blinded personnel (Appendix  10.2). 
Sample retention  
Unless otherwise specified  
 all samples collected for specified laboratory tests will be 
destroyed within 60 days of receipt of confirmed test results.  Certain samples may be retained for 
a longer period, if necessary, to comply with applicable laws, regulations, or laboratory 
certification standards . 
8.2.5.1.  Pregnancy Testing  
Pregnancy testing is to be performed on women of childbearing potential  (WOCBP)  and women 
with a history of tubal ligation . Participants  who are  pregnant will be discontinued from the study  
(Section 7.1.1 ). 
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 57 Visits and times  
Serum pregnancy test will be done at screening only, and results will be confirmed by the central 
laboratory.  
Urine pregnancy testing will be performed locally at visits specified in the SoA (Section 1.3). If 
the specified visit includes study drug administ ration, t he urine pregnancy test must be 
“negative” within 24 hours before the study drug is administered . 
Urine pregnancy testing may be performed at additional time points during the study treatment 
period and/or follow -up period, at the discretion of the investigator or if this is required by local 
regulations.  
If a urine pregnancy test is not available, a local serum pregnancy test is an acceptable 
alternative.  
Optional follicle -stimulating hormone ( FSH) testing  
The participant’s FSH level  can be obtained during screening at the discretion of the investigator  
to assist in determining whether a woman meets th e definition of “postmenopausal.”  The FSH 
level  can also be optionally obtained during the study to determine the participant’s  
postmenopausal status ( see Section 1.3 and Appendix 10.4, Section 10.4.1 ). 
8.2.6.  Tuberculosis Testing and Monitoring  
Tuberculosis testing  
During screening, all participants are to be assessed for risk factors, symptoms, and signs of TB 
with all of the following:  
●  Thoro ugh history to determine the lifetime risk factors for TB infection, for TB 
progression, and for symptoms and/or signs of active TB, and  
●  Signs of previous or active TB by means of  
−  Thorough physical examination for signs of active TB, including measurement of 
body  temperature (Section 8.2.1 ) and assessment of peripheral lymph nodes 
(Section  8.2.2 ), and 
−  PA CXR interpreted and reported by radiologist or pulmonologist (Section 8.2.4 ). 
All participants with no history of LTBI or active TB, and no history of positive Mantoux 
tuberculin skin test (TST) using purified protein derivative (PPD) or positive Mycobacterium 
tuberculosis  interferon gamma release assay (IGRA) must have one of the following.  
●  PPD TST  
−  The TST is performed by injecting 0.1 mL of tuberculin PPD into the inner surface of 
the forearm. The injection should be made with a tuberculin syringe, with the needle 
bevel facing upward. The TST is an intradermal injection. When placed correctly, the 
injection should produce a pale elevation of the skin (a wheal) 6 to 10 mm in diameter. 
Measure induration at site of intradermal injection 48 to 72 hours after intradermal  
injection. The t est must be read during this window of time. The reaction should be 
measured in millimeters of induration (palpable, raised, hardened area or swelling). 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 58 The reader should not measure erythema (redness). The diameter of the indurated area 
should be measured across the forearm (perpendicular to the long axis).  
−  An induration of 5 or more millimeters is considered positive . Two-step testing (repeat 
TST from 1 to 3 weeks after the first TST) is recommended for certain participant 
groups , based on investigator judgment , including:  
¤  persons receiving immunosuppressant treatment  
¤  persons with a history of temporally remote increased risk of TB infection  
¤  persons for whom the first test is negative, as per local public health and/or 
profes sional medical society recommendations.  
•  IGRA for M tuberculosis . Ensure that specimen handling, transport, timing, and laboratory 
procedures meet all requirements per package insert.  
Retesting  
One retest is allowed for participants with an “indeterminate” QuantiFERON -TB Gold assay or 
“borderline” T -SPOT .TB assay. Participants with 2 indeterminate QuantiFERON -TB Gold 
assays or 2 borderline T -SPOT .TB assays will be excluded.  
Diagnosed LTBI  
Participants diagnosed with LTBI are excluded (Section  5.2) unless they are candidates for LTBI 
treatment, are treated for LTBI, and the following criteria are met:  
•  After receiving at least 4 weeks of  appropriate LTBI therapy (as per World Health 
Organization and/or the United States Centers for Disease Control guidelines), there is no 
evidence of hepatotoxicity (ALT/AST must remain ≤2 times ULN) or other treatment 
intolerance. The participant may be r escreened and is not excluded due to LTBI.  
•  The participant must continue and complete appropriate LTBI therapy in order to remain 
eligible to continue to receive study intervention.  
Monitoring during the study  
For all participants, monitoring for TB is to be continuous throughout the study. At a minimum, 
each participant is to have the following documented at least every 3 months:  
•  Thorough  history to determine any risk factors for TB infection and for TB progression, 
symptoms or signs of active TB, and  
•  Physical examination that includes assessment for signs of active TB, including 
measurement of body temperature and assessment of periphe ral lymph nodes  (Section 
8.2.2 ). 
8.2.7.  Hepatitis  B Testing and Monitoring  
Initial testing for hepatitis B virus (HBV) infection includes hepatitis B surfac e antigen (HBsAg) 
and antibody to hepatitis B core antigen (anti -HBc).  
•  If HBsAg is positive, the participant is excluded.  
•  If HBsAg is negative and anti -HBc is negative, the participant is not excluded . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 59 •  If HBsA g is negative and anti -HBc is positive, further testing for HBV DNA is required.  
−  If the screening HBV DNA is positive, the participant is excluded.  
−  If the screening HBV DNA is negative, the participant is not excluded.  Repeat testing 
for HBV DNA is required at least every 3 months during the study (Section 1.3), with 
temporary withholding or permanent discontinuation of study intervention if HBV 
DNA is positive, as described in Section 7.1.2  and Section  7.1.1 , respectively.  
Management of enrolled participants with detectable HBV DNA during the study  
If HBV DNA is detected during the study, the study d rug will be temporarily withheld or 
discontinued  and participants should receive appropriate follow -up medical care as described in 
Section  7.1.1  and Section  7.1.2 . 
8.2.8.  Hepatitis C Testing and Monitoring  
Initial testing for HCV infectio n includes testing for antibodies to HCV.  
• If anti -HCV is positive, a serum test for circulating HCV RNA is required.  
• If HCV RNA test is negative, the participant is not excluded.  
• If HCV RNA test is positive, the participant  is excluded (see Section 5.2). 
Participants who have had HCV infection and been successfully treated, defined as a sustained 
virologic response (HCV RNA by PCR negativ e for at least 24 weeks following treatment 
completion) are not excluded on the basis of HCV as long as HCV RNA test is negative at 
screening.  
If HCV RNA is detected during the study, the study drug will be discontinued  (Section  7.1.1 ), 
and the participant should receive appropriate follow -up medical care.  
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 60 8.2.9.  Hepatic Safety Monitoring  
Close hepatic monitoring  
The laboratory tes ts listed in Appendix 10.5, including ALT, AST, ALP, TBL, direct bilirubin , 
gamma -glutamyl transferase ( GGT ), and creatine kinase ( CK), should be repeated within 48 to 
72 hours, to confirm the abnormality and to determine whether it is increasing or decreasing, if 
these conditions occur:  
If a participant with baseline ...  has the following elevations:  
ALT  or AST <1.5 times ULN  ALT  or AST  ≥3 times ULN  
ALP <1.5 times ULN  ALP ≥2 times ULN  
TBL <1.5 times ULN  TBL ≥2 times ULN  
  
ALT  or AST ≥1.5 times ULN  ALT  or AST  ≥2 times baseline  
ALP ≥1.5 times ULN  ALP ≥2 times baseline  
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for the 
possible causes of the abnormal liver tests should be initiated by the investigator in consultation 
with the sponsor’s designated medical monitor. At a minim um, this evaluation should include a 
physical examination and a thorough medical history, including symptoms, recent illnesses (for 
example, heart failure, systemic infection, hypotension, or seizures), recent travel, history of 
concomitant medications (including o ver-the-counter), herbal and dietary supplements, history of 
alcohol drinking, and other substance abuse.  
Initially, monitoring of symptoms and hepatic biochemical tests should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clini cal condition and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condition and lab results stabilize. Monitoring of ALT, AST, ALP and TBL 
should continue until l evels normalize or return to approximate baseline levels.  
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
these conditions occur:  
If a participant with baseline ... has the fol lowing elevations:  
ALT  or AST  <1.5 times ULN  ALT  or AST  ≥3 times ULN with hepatic signs/symptoms *, or  
ALT  or AST  ≥5 times ULN  
ALP <1.5 times ULN  ALP ≥3 times ULN  
TBL <1.5 times ULN  TBL ≥2 times ULN  
  
ALT  or AST  ≥1.5 times ULN  ALT  or AST  ≥2 times baseline with hepatic signs/symptoms *, or 
ALT  or AST ≥3 times baseline  
ALP ≥1.5 times ULN  ALP ≥2 times baseline  
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, 
fever, rash, and/or eosinophilia  >5%.  
At a minimum, this evaluation should include a physical examination and a thorough medical 
history, as outlined above, as well as tests for prothrombin time (PT -INR); viral hepatitis A, B, 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 61 C, and E; tests for autoimmune hepatitis, and an abdominal imaging study (for example, 
ultrasound or CT scan).  
Based on the participant’s  history and initial results, further testing sho uld be considered in 
consultation with the sponsor’s designated medical monitor, including tests for hepatitis D virus 
(HDV), cytomegalovirus (CMV), Epstein -Barr virus (EBV), acetaminophen levels, 
acetaminophen protein adducts, urine toxicology screen, Wil son’s disease, blood alcohol levels, 
urinary ethyl  glucuronide, and serum phosphatidylethanol.  
Based on the circumstances and the investigator’s assessment of the participant’s clinical 
condition, the investigator should consider referring the participant for a hepatologist/ 
gastroenterologist consultation, magnetic resonance cholangiopancreatography (MRCP), 
endoscopic retrograde cholangiopancreatography (ERCP), cardiac echocardiogram, or a liver 
biopsy.  
8.2.9.1.  Additional Hepatic Data Collection in Participants Wh o Have Abnormal Liver 
Tests During the Study  
Additional hepatic safety data collection (hepatic safety eCRF) should be performed for 
participants who meet one or more of the following conditions : 
●  Elevation  of serum ALT to ≥5 times ULN on two or more consecutive blood tests  (if 
baseline ALT <1.5 times ULN)  
○  In participants with baseline ALT ≥1.5 times ULN, the threshold is ALT  ≥3 times 
baseline on 2 or more consecutive tests.  
●  Elevated TBL to ≥ 2 times U LN (if baseline TBL <1.5 times ULN) (except for cases of 
known Gilbert’s syndrome)  
○  In participants with baseline TBL ≥1.5 times ULN, the threshold should be 
TBL  ≥2 times baseline.  
●  Elevation  of serum ALP to ≥2 times ULN on two or more consecutive blood tests  (if 
baseline ALP <1.5 times ULN)  
○  In participants with baseline ALP≥1.5 times ULN, the threshold is ALP  ≥2 times 
baseline on two or more consecutive blood tests.  
●  Hepatic event consid ered to be a SAE . 
●  Discontinuation of study drug due to a hepatic event  (Section 7.1.1 ). 
Note that the interval between the two consecutive blood tests should be at least 2 days.  
8.2.10.  Suicidal Ideation and Behavior Risk Monitoring  
Participants  should be monitored appropriately and observed closely for suicidal ideation and 
behavior or any other unusual changes in behavior, especially at  the beginning and end of the 
course of intervention . Participants who have signs of suicidal ideation or behavior should be 
considered for discontinuation of study drug, following a risk assessment (see Section 7.1.1 ). See 
Section  8.3.1.1  for timing of adverse event  collection relative to collection of the C -SSRS.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 62 8.2.10.1.  Columbia Suicide Self -Reported Scale (C -SSRS)  
The Columbia Suicide -Severity Rating Scale (C -SSRS) is a scale that c aptures the occurrence, 
severity, and frequency of suicidal ideation and behavior during the assessment period via a 
questionnaire. The scale was developed by the National Institute of Mental Health (NIMH) trial 
group (TASA) for the purpose of being counte rpart to the Columbia Classification Algorithm of 
Suicide Assessment (C -CASA) categorization of suicidal events.  
For this study, the C -SSRS is a dapted for the assessment of the ideation and behavior categories 
only. The Intensity of Ideation and Lethality of Behavior sections are removed.  
8.2.10.2.  Depression Assessment with 16-Item Quick Inventory of Depressive 
Symptomatology –Self Report (QIDS -SR16 ) QIDS -SR16  
The 16-Item Quick Inventory of Depressive Symptomatology –Self Report (QIDS -SR16 ) is a 
self-adminis tered, 16 -item instrument intended to assess the existence and severity of symptoms 
of depression as listed in the American Psychiatric Association’s Diagnostic and Statistical 
Manual of Mental Disorders, 5th Edition (DSM -V) (APA 2013). A participant  is asked to 
consider each statement as it relates to the way he or she has felt for the past 7  days. There is a 
4-point scale for  each item ranging from 0 to 3. The 16 items corresponding to 9 depression 
domains are summed to give a single score ranging from 0 to 27, with higher scores deno ting 
greater symptom severity. The domains assesse d by the instrument include 1) sad mood, 2) 
concentration, 3) self -criticism, 4) suici dal ideation, 5) interest, 6) energy/fatigue, 7) sleep 
disturbance (initial, middle, and l ate insomnia or hypersomnia), 8) decrease/increase in 
appetite/weight, and 9) psychomotor agitation/retardation . 
8.2.11.  Injection Site Assessment  
Symptoms of a local injection site reaction may include erythema, induration, pain, pruritus, and 
edema. See Section 6.3 for activities relating to assessment  of injection site reactions.  
Solicited Events  
Solicited data from injection  site assessments will not be rou tinely classified  as an adverse event . 
Unsolicited Events  
If a participant  reports symptoms ( that is, an unsolicited event , volunteered by participant ) or if 
the investigator determines that a clinically relevant injection  site reaction has occurred, the 
event will be captured as an adverse event . In such a case, a specific adverse event  of Injection 
site reaction will be reported and the event followed up to completion, in addition to completing 
the injection  site assessment questionnaire in the eCRF.  
8.3. Adverse Events and Serious Adverse Events  
Adverse events ( AEs) will be reported by the participant or, when appropriate, by a caregiver, 
surrogate, or the participant's legally authorized representative.  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that  meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the study intervention  or the study (see Section  7). 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 63 Pregnancy after maternal or paternal exposure to IP does not meet the definition of an AE. 
However, to fulfill regulatory requirements,  any pregnancy should be reported using the SAE 
process described in Appendix 10.3, Section 10.3.4 , to collect data on the outcome for both 
mother an d fetus. See also Section  8.3.5 . 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
All AEs will be collected from the time of the participant ’s signing of the main  Study KFAJ  ICF 
until the participant’s  last post -treatment follow -up visi t. 
Likewise, a ll SAEs will be collected from the signing the  Study KFAJ  ICF until the last 
post-treatment follow -up visit . 
Adverse events  that begin before the start of study intervention but after signing of the ICF will 
be recorded on the Adverse Event eCRF.  
Although all AEs after signing the ICF are recorded by the site in the eCRF/electronic data entry  
tool, SAE reporting to the sponsor begins after the participant  has signed the ICF and has 
received study drug . However, if an SAE occurs after signing the IC F but prior to receiving 
study drug , the SAE  needs to be reported ONLY if the SAE  is considered reasonably possibly 
related to study procedures.  
All SAEs will be recorded and reported to the sponsor or the sponsor’s designee immediately , 
and under no circumstance should this exceed 24 hours, as indicated in Appendix 10.3. The 
investigator will submit any updated SAE data to the sponso r within 24  hours of it being 
available.  
Investigators are not obligated to actively seek AE or SAE s after the conclusion of study 
participation, that is, once the participants have discontinued and/or completed the study (the 
Participant Study Disposition  eCRF has been completed) . However, if the investigator learns of 
any SAE, including a death, at any time after a participant has been discharged from the study, 
and the investigator  considers the event to be reasonably related to the study intervention or 
study participation, the i nvestigator must promptly notify the sponsor.  
8.3.1.1.  Adverse Event Monitoring with a Systematic Questionnaire  
Nonleading (s pontaneous ) AE collection should occur before  the collection of  the C -SSRS.  
If a suicide -related event is discovered during the C -SSRS  colle ction  but was not captured during 
the nonleading AE collection, sites should not change the adverse event  form.  However, i f an 
adverse event  is serious or leads to discontinuation, the adverse event  should be included on the 
adverse event  form . Also, t he process for reporting SAEs should be  followed.  
8.3.2.  Method of Detecting AEs and SAEs  
The method of recording, evaluating, and assessing causality of AE and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix  10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences . 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 64 8.3.3.  Follow -up of AEs and SAEs  
After the initial AE  or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  
 will be followed until resolution, stabilization, the event is 
otherwise explained, or the participant is lost to follow -up (Sectio n 7.3). Further information on 
follow -up procedures is provided  in Appendix  10.3.3 . 
8.3.4.  Regulatory Reporting Requirements for SAEs  
Prompt notification by the investigator to the sponsor of a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
intervention under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
sponsor will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, Institutional Review Boards (IRB)/Independent Ethics Committees 
(IEC) , and investigators.  
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information ( for ex ample , summary or listing of SAEs) from the sponsor will review and 
then file it along with the IB and will notify the IRB/IEC, if appropriate according to local 
requirements.  
8.3.5.  Pregnancy  
For female participants and female partners of male participants , details  will be collected for 
pregnancies occurring from after the start of study intervention and until 12 weeks  after the last 
dose. 
If a pregnancy is reported, the investigator should inform the sponsor within 24 hours of learning 
of the pregnancy and should follow the reporting procedures outlined in Appendix  10.4, Section 
10.4.3 . 
Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.  
  
 
 
 
 
 
8.3.6.1.  Systemic Hypersensitivity Reactions  
Many drugs, but particularly biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data describing each symptom should be p rovided 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 65 to the sponsor in the eCRF.  It is recommended that participants who experience a systemic 
hypersensitivity reaction be treated per the local standard of care.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when the study participants are receiving study drug.  
Blood sample collection for systemic allergic/hypersensitivity events , including CRS . 
In the case of generalized urticaria or anaphylaxis, additional blood samples as described in 
Appendix 10.2 should be collected. Laboratory results ar e provided to the sponsor via the central 
laboratory.  
8.3.6.2.  Serious Infections  and Opportunistic Infections  
Completion of the Infection eCRF page is required for each infection reported as an AE  or SAE. 
The sponsor will identify infections considered to be oppor tunistic based on the article by 
Winthrop et al. (2015) (Appendix  10.6). 
8.3.7.  Complaint Handling  
A product complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, durability, reliability, safety, effectiveness or performance of a 
trial intervention. The sponsor collects product complaints  on investigational products  and drug 
delivery systems  used in clinical studies in order to ensure the safety of study participants, 
monitor quality, and to facilitate process and product improvements.  
Participants will be instructed to contact the investi gator as soon as possible if they have a 
complaint or problem with the investigational product so that the situation can be assessed.  
Note:  Any AEs/SAEs that are associated with a product complaint will follow the processes 
outlined in Section  8.3.3  and Appendix 10.3.  
Time period for detecting product complaints  
Product complaints that result in an AE will be detected, documented, and reported to the 
sponsor during all periods of the study in which the d rug/device is used. If the investigator learns 
of any product complaint at any time after a participant has been discharged from the study, and 
such incident is considered reasonably related to a drug/device provided for the study, the 
investigator will pr omptly notify the sponsor.  
Prompt reporting of product complaints to the sponsor  
Product complaints will be reported to the sponsor within 24 hours after the investigator becomes 
aware of the complaint. The Product Complaint Form will be sent to the sponso r by a method 
designated by the sponsor.  
Follow -up of product complaints  
Follow -up applies to all participants, including those who discontinue study intervention. The 
investigator is responsible for ensuring that follow -up includes any supplemental investigations 
as indicated to elucidate the nature and/or causality of the product complaint . New or updated 
information will be recorded on the originally completed form with all changes signed and dated 
by the investigator and submitted to the sponsor.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 66 8.4. Treatment of Overdose  
For this study, an overdose of LY3471851 is considered any dose greater than the highest dose 
planned to be used  in this study . The treatment for suspected overdose is supportive care.  
In the event of an overdose, the investigator  should:  
1.  Contact the sponsor’s medical monitor immediately.  
2.  Closely monitor the participant for any AE  or SAE and laboratory abnormalities until the 
study intervention  can no longer be detected systemica lly (at least  12 weeks ). 
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with  the sponsor’s medical monitor based on clinical evaluation of the participant.  
8.5. Pharmacokinetics  
Visits and times  
At the visits and times specified in the SoA (Section 1.3), venous blood samples will be collected 
to determine the plasma concentrations of LY3471 851. The actual date and time (24 -hour clock 
time) of dosing and sample collection must be recorded accurately on the appropriate forms.  
Collection, handling, and analysis  of samples  
Instructions for the collection and handling of blood samples will be pro vided by the sponsor. 
Samples will be analyzed at a laboratory approved by the sponsor.  Concentrations of LY3471851 
will be assayed using a validated PK assay. Analyses of samples collected from participant s who 
received placebo are not planned . 
Additional and unused samples  
 
 
 
 
 
In the case of systemic allergic/hypersensitivity reactions , additional blood samples will be 
obtained  for PK analys es (Section  8.3.6.1 ). 
Blinding  
Drug concentration information that may unblind the study will not be reported to investigative 
sites or to personnel who are blinded to study data . 
 
 
 
  
 
 
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 67  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 68   
  
8.10. Medical Resource Utilization and Health Economic s 
This section is not applicable.  
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 69 9. Statistical Considerations  
9.1. Statistical Hypotheses  
The null hypothesis for the primary endpoint is that there is no difference between LY3471851  
and placebo in reducing the signs and symptoms of SLE as measured by the p roportion of 
participants who achieve a SLEDAI -4 response at  Week  24. 
9.2. Sample Size Determination  
will be randomly assigned to study intervention. All randomized 
participants in the modified intent -to-treat (mITT) population will be considered evaluable.  
Pairwise 2 -sided tests of proportions with alpha = 0.05 will be performed on each LY3471851 
dose versus pla cebo. With 70 participants per group, Study KFAJ has  at least 80% power to 
detect a statistically -significant difference of 24% improvement over placebo  in SLEDAI -4 
response between LY3471851 and placebo at Week 24.  
9.3. Populations for Analyses  
The mITT popul ation, which includes a ll randomized participants  receiving at least 1 dose of 
study intervention , will be used in analyses of efficacy  and patient -reported outcomes  (PRO) , 
unless otherwise noted in the SAP).  
The following populations are defined  for this study : 
Population  Description  
Entered  All participants who sign the informed consent form  
Modified Intent -to-Treat (mITT)  All participants randomly assigned to study intervention and who take at least 
1 dose of study intervention. Participants will be analyzed according to the 
intervention to which they were assigned.  
Safety  All participants randomly assigned to study intervention and who take at least 
1 dose of study intervention. Participants will be analyzed according to the 
intervention they actually received  within each study period.  
Pharmacokinetic (PK) Analysis  All participants randomly assigned to study intervention and who take at least 
1 dose of study intervention and have PK data available.  
 
9.4. Statistical Analyses  
9.4.1.  General Considerations  
 Unless 
other indicated in the SAP, the analyses will be conducted as follows:  
●  Primary and secondary endpoint analyses will be tested at a 2 -sided  level of 0.05 for 
frequentist analyses.  
●  The primary estimand that will b e used to analyze primary and secondary endpoints is a 
composite response estimand where c omparisons will not include data collected after 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 70 intercurrent events of changes to background therapies or discontinuation . Participants  
who discontinue treatment pri or to 24 weeks or who are noncompliant with concomitant 
medication rules are defined as nonresponders . Endpoint definition effectively gives 
complete data  which will be analyzed as described in  Section  9.4.2  and Section 9.4.3 . 
●  No adjustments for  multiplicity will be performed . 
●  Efficacy and PRO analysis models may contain the independent variables such as 
treatment group, baseline disease activity, and geographic region . 
●  Missing data for dichotomous responder endpoints will be imputed using the 
nonresponder imp utation (NRI) method . 
●  Participants  will be considered nonresponders for the NRI analysis  if 
○  they do not meet all the clinical response criteria  
○  they are noncompliant with concomitant medication rules (Section 6.5) 
○  they permanently discontinue  study intervention  at any time  before the  end of  the 
treatment period for any reason , or 
○  they are randomized and do not have  at least 1 postbaseline observation . 
●  Mixed -effect s model for repeat ed measure s (MMRM ) is the main method for analyzing 
continuous efficacy endpoints .  
●  Additional imputation methods may be considered for all endpoint types.  
Baseline will be defined as the last available value before the first dose of study intervention for 
both efficacy and safety analyses. In most cases, this value will be what is recorded at the 
randomization visit (Visit 2). Change from baseline will be calculated as the visit value of 
interest minus the baseline value. For the post -treatment Follow -up Period, the base line is 
defined as the last nonmissing assessment on or prior to entering the post -treatment Follow -up 
Period, that is, on or prior to the Week 24 visit, or the early termination  visit (including ETV).  
Any change to the data analysis methods described in t he protocol will require an amendment 
only if the change affects  a principal feature of the protocol. Any other change to the data 
analysis methods described in the protocol, and the justification for making the change, will be 
described in the SAP and the  clinical study report.  
 
The SAP will be finalized prior to  unblinding . It will include a more technical and detailed 
description of the statistical analyses described in t his section. This section is a summary of the 
planned statistical analyses of the primary and secondary endpoints.  
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 71 9.4.1.1.  Participant Disposition  
A detailed description of participant  disposition will be provided, including a summary of the 
number and percentage of participants  entered into the study  and randomized , and number and 
percentage of participants  who complet e the study  or discontinu e, both overall and by reason for 
discontinuation. A summary of important protocol deviations will be provided.  
9.4.1.2.  Participant Characteristics  
Demographic data are collected and responded to demonstrate that the study population 
represents the target patient population. A summary of baseline participant characteristics, 
historical diagnoses, preexisting conditions, and  prior therapies will be reported by treatment 
group using descriptive statistics . Other participant characteristics will be summarized by 
treatment group as deemed appropriate.  
9.4.1.3.  Concomitant Therapy  
Previous and concomitant medications will be summarized by treatment group and will be 
presented by Anatomical Therapeutic Chemical (ATC) drug classes using the latest version of 
the World Health Organization (WHO) drug dictionary . 
Participant s who require initiation or increase in dosage of corticosteroids, anti malarials, or 
immunosuppressants after randomization will be analyzed as nonresponders from the day o f 
initiation or increase in medication  (see Section 6.5). 
9.4.1.4.  Treatment Compliance  
No analyses are planned to assess treatment compliance , given that participants  will receive 
study intervention directly from the investigator or designee  at the study site , under medical 
supervision  (Section 6.4). 
9.4.2.  Primary Endpoints  
The primary endpoint is the SLEDAI -4 response rate at Week 24  for the LY3471851 treatment 
group compared to placebo . Participa nts who fail to complete the 24 -week treatment period or 
violate the concomitant medication rules will be imputed to nonresponse for the purpose of the 
primary endpoint analysis. The objective of the primary endpoint is to determine whether 
LY3471851 is su perior to placebo.  
The primary endpoint will be analyzed using a logistic regression model with baseline disease 
activity, corticosteroid dose at baseline , and geographic region as model covariates . 
Treatment difference and 95% CIs will be reported.  
9.4.3.  Secondary Efficacy Endpoints  
Secondary efficacy endpoints include the following at Week 24:  
●  the proportion of participants who achieve a BILAG -based Composite Lupus Assessment 
(BICLA)  response  
●  the proportion of participants who achieve SRI -4 response , and  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 72 ●  the proportion of participants who achieve LLDAS . 
Dichotomous secondary endpoints will be analyzed using the model specified for the primary 
analysis.  
9.4.3.1.  Pharmacokinetic Analysis  
Plasma  concentrations of LY3471851 will be listed by time poi nt using descriptive statistics.  
 
 
 
 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
9.4.5.  Safety Analyse s 
Safety analyses will include AEs, SAEs, C-SSRS, QIDS -SR16 , vital signs, ECGs, and 
laboratory analytes , using the Safety Population data descriptively summarized by treatment 
group . Categorical safety measures will be summarized with incidence rates. Continuous safety 
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 73 measures will be summarized as m ean change by visit . Exposure to study  intervention will be 
calculated for each participant  and summarized by treatment group.  
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities  
(MedDRA) and summarized by system organ class, preferred term, severity, and relationship to 
the study intervention . A treatment -emergent adverse event (TEAE) is defined as an event that 
first occurred or worsened in severity after baseline , with baseline defined a s all pre-existing 
conditions recorded at Visit 1  and any AEs recorded before  the first dose of study intervention  
(that is, during  the interval between  Visits 1 and 2 and recorded with the time of onset before the 
first dose  of study intervention ). The tr eatment period will be used as the postbaseline period for 
the analysis. For events that are gender specific, the denominator and computation of the 
percentage will include only participants from the given gender.  
The n umber and percentage of participant s who experienced TEAEs, TEAEs by maximum 
severity, deaths, SAEs, TEAEs related to study intervention , discontinuations from the treatment 
due to an AE,  will be summarized . Treatment -emergent adverse events (all, by 
maximum severi ty), SAEs includin g deaths, and AEs that lead to treatment discontinuation will 
be summarized and analyzed by MedDRA system organ class (SOC) and preferred term.  
Treatment -related TEAEs (TEAEs related to study intervention)  are defined as events that are 
indicated by the in vestigator on the eCRF to be related to treatment.  
 
 
Suicide -related thoughts and behaviors occurring during treatment will be summarized based on 
responses to the C -SSRS consistent with the C -SSRS Scoring and Data Analysis Guide 
(Columbia Lighthouse Project WWW).  
Follow -up emergent AEs, SAEs including deaths, and AEs that lead to study discontinuation will 
be summarized . All AEs,  including pre -existing conditions, will be listed by participant , visit, 
preferred term, treatment group, severity, and relationship to the treatment . 
9.4.6.  Other Analyse s  
9.4.6.1.  Subgroup Analyses  
Subgroup analyses may be conducted for the primary endpoint SLEDAI -4 at Week 24  using the 
mITT  population. Subgroups that may be evaluated include interferon gene signature status,  
gender, race, geographic region,  
 previous therapies, and disease duration,  
9.4.6.2.  Supplemental Analyses  
Supplemental analyses will be performed on the primary endpoint using a treatment policy 
estimand where c omparison s will be made while on treatment , but without regard to changes to 
background therapies or premature discontinuation . When using a treatment policy estimand, 
data will be analyzed using a logistic random effects model with treatment, baseline, visit, and 
visit-by-treatment interaction.  Additional analyses of secondary endpoints may be performed 
using the same treatment policy estimand.  Analysis details are in the statistical analysis plan.  
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 74   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9.6. Data Monitoring Committee (DMC)  
Not applicable. An IAC will be used to conduct the interim analysis (see Section 9.5 and 
Appendix  10.1, Section  Appendix 10.1.5 ). 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 75 10. Supporting Documentation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
●  Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) Internati onal Ethical Guidelines  
●  Applicable International Council for Harmonisation (ICH)  Good Clinical Practice (GCP) 
Guidelines , and  
●  Applicable laws and regulations . 
The protocol, protocol amendments  and addenda , ICF, I B, and other relevant documents ( for 
example , advertisements) must be submitted to an IRB/IEC by the investigator and reviewed and 
approved by the IRB/IEC  before the study is initiated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
The investigator will be responsible for the following:  
●  Substantial amendments to the protocol require European Competent  Authority approval 
before implem entation.  
●  Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
the IRB/IEC  
●  Notifying the IRB/IEC of SAEs or other significant sa fety findings as required by 
IRB/IEC procedures , and  
●  Providing oversight of the conduct of the study at the site and adherence to requirements 
of 21 United States Code of Federal Regulations ( CFR ), ICH guidelines, the IRB/IEC, 
European regulation 536/20 14 for clinical studies (if applicable), and all other applicable 
local regulations . 
●  After reading the protocol, each principal investigator will sign the separate protocol 
signature page and send a copy of the signed page to a Lilly representative.  
Investigator sites are compensated for participation in the study as detailed in the clinical trial 
agreement.  
10.1.2.  Financial Disclosure  
Investigators and subinvestigators  will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 76 certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
respon sible for providing information on financial interests during the course of the study and for 
one year after completion of the study.  
10.1.3.  Informed Consent Process  
The investigator or his  or her representative will explain the nature of the study , including the  
risks and benefits,  to the participant or his  or her legally authorized representative and answer all  
questions regarding the study.  
Participants must be informed that their participation is voluntary.  
Participant s or their  legally authorized representati ves will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, 
and the I RB/IEC or study c enter.  The sponsor or its representatives must approve the ICFs, 
including any changes made by the ERB /IEC s, before the ICFs are used at the investigative sites.  
The medical record must include a statement that written informed consent was obtained before 
the participant was entered in the study . The statement must include the date on which the 
written consent was obtained. The authorized person obtaining the informed consent must also 
sign the ICF s. 
Participants who are rescreened are required to sign a new ICF (see Section 5.4). 
Participants must be re -consented to the most current version of the ICF during th eir 
participation in the study.  
A copy of the ICFs must be provided to the participant or the participant’s legally authorized 
representati ve and must be  kept on file . 
10.1.4.  Data Protection  
Participants will be assigned a unique ident ifier by the sponsor. Any participant records , datasets  
or tissue samples  that are transferred to the sponsor will contain the identifier only; participant 
names or any information which would make the participant identi fiable will not be transferred.  
The participant must be informed that his  or her personal study -related data will be used by the 
sponsor in accordance with local data protection law. The level of disclosure must also b e 
explained to the participant  who will be required to give consent for his or her  data to be used as 
described in the informed consent . 
The participant must be informed that his  or her medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IR B/IEC members, and by inspectors from regulatory authorities.  
10.1.5.  Committees Structure  
Eligibility Review Committee  
An eligibility review committe e, also called adjudication panel, will review study entry data to 
ensure that prospective study participants meet the study entry criteria, particularly SLE disease 
activity criteria, prior to randomization. In addition, the committee will help ensure that  high 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 77 quality data are entered into the electronic lupus assessment system. The committee may include 
member s of a third -party organization , members of the study team, and external SLE consultants 
as needed. Membership, responsibilities, operations, and me asures to maintain confidentiality 
will be described in a committee charter.  
Internal Assessment Committee (IAC)  
In addition to the safety reviews routinely performed by the blinded study team, an IAC will 
review the safety data in an unblinded fashion per iodically or on an ad hoc basis during the study 
and will determine whether any changes ( for example , dose reductions  or other protocol 
modifications ) should be made  (see also Section 10.1.9 ). 
The IAC reviewing the safety data will be fully independent from the study team and will 
include, at a minimum, a Lilly medical physician, a statistician, and a representative from the 
Lilly Global Patient Safety  organization. Details about IAC membership, purpose, 
responsibilities, and operation will be described in an IAC charter, which will be approved prior 
to the first unblinding . 
 
 
10.1.6.  Dissemination of Clinical Study Data  
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly  available websites where requi red by local law or regulation.  
 
 
 
 
 
  
 
 
 
  
 
 
10.1.7.  Data Quality Assurance  
Investigator responsibilities  
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically ( for example , laboratory data).  
The investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF.  
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 78 The investigator must maintain accurate documentation (source data) that supports the 
information entered in  the eCRF.  This documentation might include laboratory and diagnostic 
test reports, medical records, and clinical notes.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct a ccess to source data documents.  
Data monitoring and management  
Monitoring details describing s trategy ( for example , risk -based initiatives in operations and 
quality , such as risk management and mitigation strategies and analytical risk -based monitorin g), 
methods, responsibilities and requirements, including handling of noncompliance issues and 
moni toring techniques are provided in the Monitoring Plan.  
The sponsor or designee is responsible for the data management of this study , includin g quality 
checking of the data.  The sponsor assumes accountability for actions delegated to other 
individuals ( for example , contract research organizations ). 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the eCRF by authorized site personnel are accurate, complete, and verifiable from source 
documents; that the safety an d rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regu latory requirements.  
Records retention and audits  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by the investigator for 15 years after study completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during the 
retention period without the written approval of the sponsor.  No records may be transferred to 
another location or party without written notification to the sponsor . 
In addition, the sponsor  or its representatives will periodica lly check a sample of the participant 
data recorded against source documents at the study site. The study may be audited by the 
sponsor  or its representatives, and/or regulatory agencies at any time. Investigators will be given 
notice before an audit occur s. 
Data Capture System  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor.  
An electronic data capture system (EDC) will be used in this study for the collection of eCRF 
data. The investigator maintains a separate source for the data entered by the investigator or 
designee into the sponsor -provided EDC system. The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by signing the  eCRF . 
Additionally, some of the clinician -administered questionnaires data will be collected by the 
investigative site personnel , via a paper source document and will be transcribed by the 
investigative site personnel into the EDC system.  See the S oA (Section 1.3) for scales 
administered via paper.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 79 Additionally, electronic clinical outcome assessment (eCOA) data ( patient -reported  outcome and 
clinician -administered questionnaires ) will be directly recorded by the participant  and 
investigat ive site personnel , into an instrument ( for example, tablet ). The eCOA data will serve 
as the source documentation and the investigator does not maintain a separate , written or 
electronic record of these data. See the SoA (Section 1.3) for scales administered electronically.  
Data collected via the sponsor -provided data capture system s will be  stored at  third parties . The 
investigator will have continuous access to the data during the study and until de commissioning 
of the data capture system s. Prior to decommissioning, the investigator will receive an archival 
copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the centra l vendor’s database system and reports  will be provided to the investigator for review 
and retention. Data will subsequently be transferred from the central vendor to the sponsor ’s data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.8.  Source Documents  
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the d ata collected. Source documents are filed at the investigator’s site.  
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents , or the discrepancies must be explained. The 
inves tigator may need to request previous medical records or transfer records, depending on the 
study. Also, current medical records must be available.  
The d efinition of what constitutes source data can be found in Section 10.1.7 . 
10.1.9.  Study and Site Start and Closure  
The study start date is the date on which the clinical study is open for recruitment of participants . 
The sponsor or designee reserves the right to close the study site or to terminate the study at any 
time for any reason at the sole discretion of the sponsor.  
Closure of study sites  
Study sites will be closed upon study completion. A study site is considered closed when all 
required documents and study supplies have been collected and a study -site closure visit has 
been performed.  
The investigator may initiate study -site closure at any time, provided a reasonable cause exists 
and sufficient notice is given in advance of t he intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include , but are 
not limited to , these : 
●  Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health au thorities, the sponsor's procedures, or GCP guidelines  
●  Inadequate recruitment of participants by the investigator , and  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 80 ●  Discontinuation of further study intervention development . 
 
Study stopping rules  
The IAC will convene to evaluate unblinded safety data if  
●  5 or more participants experience TEAEs in the same SOC  or 3 or more participants 
experience a TEAE of CRS , and  
●  these TEAEs are judged as either serious or severe, and  
●  these TEAEs are related to blinded study tr eatment.  
Study enrollment and/or further dosing may be stopped, pending the decision of the IAC 
 Section 10.1.5 ). If the study is not stopped , the IAC will meet periodically; 
details are provided in the IAC charter . 
 
 
 
If the study is prematurely t erminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organizations 
used in the study of the reason for termination or suspension, as specified by the applicable 
regulatory requirements. The investigator shall promptly inform t he participant  and assure 
appropriate participant  therapy and/or follow -up. 
10.1.10.  Publication Policy  
In accordance with the sponsor’s publication policy , the results of this study will be submitted 
for publication by a peer -reviewed journal.  
10.1.11.  Investigator Informa tion 
Physicians with a specialty in rheumatology will participate as investigators in this clinical trial.  
Physicians and other qualified healthcare professionals with other specialties and experience in 
treatment of patients with SLE may also participate as investigators . 
10.1.12.  Long -Term Sample Retention  
Sample retention enables use of new technologies, response to regulatory questions, and 
investigation of variable response s that may not be observed until later in the development of   
LY3471851  or after LY3471851  becomes commercially available.  
The following table lists the maximum retention period for sample types. The retention period 
begins after the last participant visit for the study.  
The maximum retention times may be shorter , if specified in local regulations and/or  if 
ERBs/IRB s impose shorter time limits.  
Any samples remaining after the specified retention period  will be destroyed.  
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 81 The sample retention facility will be selected by the sponsor  or its designee . 
Sample Type  Custodian  Retention Period after Last Participant Visit  
Pharmacokinetics  Sponsor or designee  2 years 
    
   
   
 
  
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 82 10.2. Appendix 2: Clinical Laboratory Tests  
The clinical laboratory tests listed  in the table below  will be performed by a central laboratory  or 
by a local laboratory  as specified in the table . 
Additional tests may be performed at any time during the study as determined necessary by the 
investigator or as required by local regulations.  
Protocol -specific requirements for the inclusion or exclusion of participants are specified  in 
Section 5 of the protocol.  
Pregnancy testing is described in the SoA  (Section 1.3), in Section 8.2.5.1 , and in the table 
below.  
Investigators must document their revie w of each laboratory safety report.  
Laboratory test results that could unblind the study will not be reported to investigative sites or 
other blinded personnel.  
If tests are done to obtain  laboratory results with an intent to resume the study drug after a 
temporary withholding , the samples must be assayed centrally . 
 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 83 Clinical Laboratory Tests  
Hematology  a Clinical Chemistry  a 
Hemoglobin  Sodium  
Hematocrit  Potassium  
Erythrocyte count (RBCs)  Chloride  
Mean cell volume  Bicarbonate  
Mean cell hemoglobin  Total bilirubin  (TBL)  
Mean cell hemoglobin concentration  Direct bilirubin  
Leukocytes (WBCs)  Alkaline phosphatase (ALP)  
Absolute count of  Alanine aminotransferase (ALT)  
   Neutrophils, segmented  Aspartate  aminotransferase ( AST ) 
   Neutrophils, juvenile (bands)  Gamma -glutamyl transferase (GGT)  
   Lymphocytes  Blood urea nitrogen (BUN)  
   Monocytes  Creatinine  
   Eosinophils  Creatine kinase (CK)  
   Basophils  Uric acid  
Platelets Total protein  
Cell morphology  (RBC and WBC)  Albumin  
 Calcium  
Urinalysis  a Phosphorus  
Specific gravity  Glucose  
pH Amylase  
Protein  Lipase  
Glucose  Cholesterol (total)  
Ketones  Triglycerides  
Bilirubin   
Urobilinogen   
Blood  Lipid Panel a 
Nitrite  High-density lipoprotein  (HDL)  
Urine leukocyte esterase  Low-density lipoprotein  (LDL)  
Microscopic examination of sediment   
  
Urine Chemistry  a Hormones (female)  
Total protein  Pregnancy test (serum  a and urine  b) 
Creatinine  Follicle -stimulating hormone ( FSH) a, c 
  
Calculation  a  
Urine protein/urine creatinine ratio   
Estimated glomerular filtration rate (eGFR; 
calculated using the Modification of Diet in 
Renal Disease [MDRD])   
 table continues  
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 85 Selected tests may be obtained in the event of anaphylaxis or systemic allergic/hypersensitivity 
reactions . The samples sho uld be collected as close as possible to the onset of the event . 
Hypersensitivity Tests  a 
LY concentration (PK)  N-methylhistamine  
 Complements  
 Cytokine panel  
Abbreviation: PK = pharmacokinetic . 
a Assayed by Lilly -designated laboratory . 
 
 
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 91 10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information  
10.4.1.  Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below). If fertility is unclear (for example, amenorrhea in 
adolescents or athletes) and a menstrual cycle ca nnot be confirmed before first dose of study 
intervention, consider additional evaluation.  
Woman NOT of Childbearing Potential ( not-WOCBP)  
Women in the following categories are not considered WOCBP:  
●  Premenarchal  
●  Premenopausal female with 1 of the fol lowing:  
○  Documented hysterectomy  
○  Documented bilateral salpingectomy  
○  Documented bilateral oophorectomy  
For individuals with permanent infertility due to an alternate medical cause other than the 
above (for example, mullerian agenesis, androgen insen sitivity), apply investigator 
discretion to determining study entry. Determination can come from the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  
●  Postmenopausal female, defined as women  meeting one of the following criteria : 
○  At least 6 weeks post -surgical bilateral oophorectomy with or without hysterectomy, 
confirmed by operative note  
○  Spontaneous amenorrhea for at least 12 months, not induced by a medical condition 
such as anorexia  nervosa and not taking medications during the amenorrhea (for 
example , oral contraceptives, hormones, gonadotropin -releasing hormone, 
anti-estrogens, selective estrogen receptor modulators [SERMs ], or chemotherapy 
that induced the amenorrhea ); additionall y, if less than or equal to 50 years of age , 
has a FSH  of ≥40 mIU/mL  
○  At least 40 years of age with an intact uterus, not on hormone therapy, with 
cessation of menses for at least 1 year , and  without an alternative medical cause, 
AND  a FSH of ≥40 mIU/mL 
○  At least  55 years of age, not on hormone therapy, having  at least 12 months of 
spontaneous amenorrhea  
○  At least 55 years of age with a diagnosis of menopause prior to starting hormone 
replacement therapy.  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 92 10.4.2.  Contraception  
Females  
Women of childbearin g potential  
Women of childbearing potential who are abstinent (if this is complete abstinence, as their 
preferred and usual lifestyle) or in a same sex relationship (as part of their preferred and usual 
lifestyle) must agree to either remain abstinent or stay in a sam e sex relationship without sexual 
relationships with males. Periodic abstinence ( for example , calendar, ovulation, symptothermal, 
post-ovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal 
are not acceptable methods  of contraception.  
Otherwise, women of childbearing potential participating must agree to use 2 forms of effective 
contraception, where at least one form is highly effective  (less than 1% failure rate), for the 
entirety of the study. Contraception must con tinue following completion of study drug 
administration for 12 weeks . 
●  Women of child -bearing potential participating must test negative for pregnancy prior to 
initiation of treatment as indicated by a negative serum pregnancy test at the screening 
visit followed by a negative urine pregnancy test within 24 hours prior to exposure.  
●  Two forms of effective contraception, where at least one form is highly effective (such as 
combination oral contraceptives, implanted contraceptives or intrauterine devices) , will be 
used. Effective contraception (such as male or female condoms with spermicid e, 
diaphragms with spermicide or cervical sponges) may be used as the second therapy. 
Barrier protection methods without concomitant use of a spermicide are not a reliable or 
acceptable method.  Thus, each barrier method must include use of a spermicide ( that is, 
condom with spermicide, diaphragm with spermicide, female condom with spermicide). It 
should be noted that the use of male and female condoms as a double -barrier method is 
not considered acceptable due to the high failure rate when these methods are  combined.  
Women not of child -bearing potential  (not-WOCBP)  
Women who are  not-WOCBP may participate in the study  if they meet all study entry criteria . 
For such women, t here are no conception requirements.  
Males  
No male contraception is required except in compliance with specific local government study 
requirements . 
10.4.3.  Collection of Pregnancy Information  
Male participants wi th partners who become pregnant  
The investigator will attempt to collect pregnancy information on any male participant’s female 
partner wh o becomes pregnant while the male participant is in this study. This applies only to 
male participants who receive study intervention . 
After obtaining the necessary signed informed consent from the pregnant female partner directly, 
the investigator will record pregnancy information on the appropriate form and submit it to the 
sponsor within 24 hours  of learning of the partner’s pregnancy.  The female partner will be 
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 93 followed to determine the outcome of the pregnancy.  Information on the status of the mother and 
child will be forwarded to the sponsor.  Generally, the follow -up will be no longer than 6 to 
8 weeks following the estimated deliver y date. Any termination of the pregnancy will be 
reported regardless of fetal status (presence or absence of anomalies) or indication for the 
procedure.  
Female participants who become pregnant  
The investigator will collect pregnancy information on any fem ale participant who becomes 
pregnant while participating in this study. The initial information will be recorded on the 
appropriate form and submitted to the sponsor within 24 hours of learning of a participant's 
pregnancy.  
The participant will be followed  to determine the outcome of the pregnancy. The investigator 
will collect follow -up information on the participant and the neonate , and the information will be 
forwarded to the sponsor. Generally, follow -up will not be required for longer than 6 to 8 weeks  
beyond the estimated delivery date. Any termination of pregnancy will be reported, regardless of 
fetal status (presence or absence of anomalies) or indication for the procedure.  
While pregnancy itself is not considered to be an AE or SAE, any pregnancy co mplication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth (occurring at 
>22 weeks gestational age) is always considered to be an SA E and will be reported as such.  
Any post -study pregnancy -related SAE considered reasonably related to the study intervention 
by the investigator will be reported to the sponsor as described in Section  8.3.4 . While the 
investigator is not obligated to actively seek this information in former study participants, he or 
she may learn of an SAE through spontaneous reporting.  
Any female participant who becomes pregnant while participating in the study will discontinue 
study intervention and be withdrawn from the study . 
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 94 10.5. Appendix 5: Liver Safety: Hepatic Monitoring Tests  
Sample s for selected tests may be obtained in the event of a treatment -emergent hepatic 
abnormality  and may be required during follow -up with participants in consultation with the 
clinical research physician of the sponsor or sponsor’s designee.  
Hepatic Monitorin g Tests  
Hepatic Hematology a Haptoglobin a 
Hemoglobin   
Hematocrit  Hepatic Coagulation a 
RBC  Prothrombin Time  
WBC  Prothrombin Time, INR  
Neutrophils, segmented   
Lymphocytes  Hepatic Serologies a,b 
Monocytes  Hepatitis A antibody, total  
Eosinophils  Hepatitis A antibody, IgM  
Basophils  Hepatitis B surface antigen  
Platelets  Hepatitis B surface antibody  
 Hepatitis B core antibody  
Hepatic Chemistry a Hepatitis C antibody  
Total bilirubin  Hepatitis E antibody, IgG  
Direct bilirubin  Hepatitis E antibody, IgM  
Alkaline phosphatase   
ALT  Antinuclear antibody a 
AST   
GGT  Alkaline Phosphatase Isoenzymes a 
CPK   
 
 Anti -smooth muscle antibody (or anti -actin antibody) a 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl  transferase; Ig = immunoglobulin; INR = international normalised 
ratio; RBC = red blood cells; WBC = white blood cells.  
a Assayed by Sponsor -designated or local laboratory.  
b Reflex/confirmation dependent on regulatory requirements and/or testing availability.  
 
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 95 10.6. Appendix 6: Examples of Infections That May Be Considered 
Opportunistic  in the Setting of Biologic Therapy  
The following table lists examples of infections that may be considered opportunistic in the 
setting of biologic therapy (adapted from Winthrop et al. [2015]). This table is provided to aid 
the investigator in recognizing such infections. This list is not exhaustive. Infections will be 
categorized by Lilly as opportunistic according to Opportunistic Infections and Biologic 
Therapies in Immune -Mediated Inflammatory Diseases: Consensus Recommendations for 
Infection Reporting during Clinical Trials and Postmar keting Surveillance  by 
Winthrop  et al. (2015).  
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 96 Examples of Infections That May  Be Considered Opportunistic in the Setting of Biologic 
Therapy  
Bacterial  
 Bartonellosis (disseminated disease only)  
 Campylobacteriosis (invasive disease only)  
 Legionellosis  
 Listeriosis (invasive disease only)  
 Nocardiosis  
 Tuberculosis  
 Non-tuberculous mycobacterial disease  
 Salmonellosis (invasive disease only)  
 Shigellosis (invasive disease only)  
 Vibriosis (invasive disease due to Vibrio vulnificus ) 
Viral  
 BK virus disease including polyomavirus -associated nephropathy  
 Cytomegalovirus disease  
 Hepatitis B virus reactivation  
 Hepatitis C virus progression  
 Herpes simplex (invasive disease only)  
 Herpes zoster (any form)  
 Post-transplant lymphoproliferative disorder (Epstein -Barr virus)  
 Progressive multifocal leukoencephalopathy (PML), John Cunningham (JC) virus  
Fungal  
 Aspergillosis (invasive disease only)  
 Blastomycosis  
 Candidiasis (invasive disease or oropharyngeal, esophageal. Not isolated lingual .) 
 Coccidioidomycosis  
 Cryptococcosis  
 Histoplasmosis  
 Paracoccidioides  infections  
 Penicilliosis  
 Pneumocystosis  
 Sporotrichosis  
 Other invasive molds: Mucormycosis (zygomycosis) ( Rhizopus , Mucor,  and Lichtheimia ), 
Scedosporium /Pseudallescheria boydii , Fusarium  
Parasitic  
 Leishmaniasis (visceral only)  
 Strongyloidosis (hyperinfection  syndrome or disseminated disease)  
 Microsporidiosis  
 Toxoplasmosis  
 Trypanosoma cruzi  infection (Chagas’ disease progression) (disseminated disease only)  
 Cryptosporidiosis (chronic disease only)  
Source: Adapted from Winthrop et al. (2015).  
  
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 97 10.7. Appendix 7: Efficacy and Patient -Reported Outcomes Assessments  
 the 
outcome measures used in this study are standard, widely used, and generally recognized as 
reliable, accurate, and relevant . 
10.7.1.  British Isles Lupus Assessment Group 2004 (BILAG -2004 ) 
The BILAG 2004 index is a validated global disease activity index designed on the basis of the 
physician’s intent -to-treat, focusing on changes in disease manifestatio ns (not present, improving, 
same, worse, or new) occurring in the last 4 weeks compared with the previous 4  weeks. The 
instrument assesses 97 clinical signs, symptoms, and laboratory parameters across 9 organ 
system domains: constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, 
cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematology.  
●  The BILAG A disease activity score is severe disease activity requiring high -dosage oral 
or intravenous corticosteroids, immunomodulators, or high -dosage anticoagulation along 
with high -dosage corticosteroids or immunomodulators.  
●  The BILAG B disease activity score is moderate disease activity requiring low -dosage oral 
corticosteroids, intramuscular or intra -articular corticosteroid injections, to pical 
corticosteroids or immunomodulators, antimalarials, or symptomatic therapy.  
●  The BILAG C corresponds to stable, mild disease . 
●  The BILAG D is inactive disease that was active previously . 
●  The BILAG E indicates the system was never involved.  
  
 
 
 
 
 
10.7.3.  Physician’s Global Assessment  (PGA ) of Disease Activity – Visual Analog Scale  
The PGA  of Disease Activity is the physician’s assessment of the participant’s  overall disease 
activity because of SLE , as compared with all possib le subjects with SLE. The PGA  of Disease 
Activity is scored using a 100 -mm visual analog scale, where 0 mm (measured from the left 
starting point of the line) indicates no disease activity , and 100 mm (measured from the left 
starting point of the line) ind icates severe disease activity. The PGA  of Disease Activity score is 
indicated by making a vertical tick mark on the line between 0 and 100 mm. There are 
benchmarks of 0 (0 mm), 1 (33 mm), 2 (67 mm), and 3  (100 mm) on the line corresponding to no, 
mild, mo derate, and severe SLE disease activity, respectively.  
10.7.4.  Systemic Lupus Erythematosus Disease Activity Index 2000  (SLEDAI -2K) 
The SLEDAI -2K is a validated global disease activity instrument that focuses on disease 
manifestations across 9 organ systems. It in cludes 24 clinical and laboratory variables with 
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 98 manifestations graded by the affected organ system as follows: Central nervous system  (CNS) 
(seizure, psychosis, organic brain syndrome, visual disturbance, cranial nerve disorder, lupus 
headache, cerebral vascular accident); Vascular (vasculitis); Musculoskeletal (arthritis, myositis); 
Renal (urinary casts, hematuria, proteinuria, pyuria); Mucocutaneous (rash, alopecia, mucosal 
ulcers); Cardiovascular and Respiratory (pleurisy, pericarditis); Immun ologic (low complement, 
increased DNA binding); Constitutional (fever); and Hematologic (thrombocytopenia, 
leukopenia).  
10.7.5.  Systemic Lupus Erythematosus Disease Activity Index  (SLEDAI ) Flare Index  
The SLEDAI Flare Index uses the SLEDAI -2K score, disease activi ty scenarios, treatment 
changes, and Physician’s Global Assessment (PGA) of Disease Activity to define mild/moderate 
and severe flares. The index takes into account the absolute change in total scores, new or 
worsening symptoms, and increases in medication  use or hospitalization because of the disease 
activity . 
  
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
  
 
 
 
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 99   
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 100  
 
  
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 101 10.8. Appendix 8: Abbreviations  
 
Term  Definition  
  
AE adverse event  
  
ALC absolute lymphocyte count  
ALP alkaline phosphatase  
ALT alanine aminotransferase  
ANA  antinuclear antibod y 
ANC  absolute neutrophil count  
anti-HBc antibody to hepatitis B core antigen  
AST aspartate aminotransferase  
AUC  area under the concentration versus time curve  
BICLA  BILAG -based Composite Lupus Assessment  
BILAG  British Isles Lupus Assessment Group  
blinding  A double -blind study is one in which neither the participant  nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the subjects 
are aware of the treatment received.  
CBD  cannabidiol  
CFR United States Code of Federal Regulations  
CK creatine kinase  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.  
CPK  creatinine  phosphokinase  
clinical research 
physician  Individual responsible for the medical conduct of the study. Responsibilities of the 
clinical research physician  may be performed by a physician,  clinical research scientist, 
global safety physician or other medical officer.  
COA  clinical outcome assessment  
CRF case report form  
CRS  cytokine release syndrome  
C-SSRS  Columbia –Suicide Severity Rating Scale  
CT compute d tomography  
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 102 CXR  chest x-ray 
DMC  data monitoring committee  
DNA  deoxyribonucleic acid  
ECG  electrocardiogram  
eCOA  electronic clinical outcome assessment  
eCRF  electronic case report form  
EDC  electronic data capture system  
enroll  The act of assigning a participant  to a treatment. Participants  who are enrolled in the 
study are those who have been assigned to a treatment.  
enrollment  The act or time point of randomization, or the condition of have been assigned to a 
treatment  (randomized).  
enter  Participants  entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.  
ERB  Ethical Review Board (see IRB)  
ETV early termination  visit 
FSH follicle -stimulating hormone  
GCP  good clinical practice  
GGT  gamma -glutamyl transferase  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCV  hepatitis C virus  
HIV human immunodeficiency virus  
IAC internal assessment committee  
IB Investigator’s Brochure  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee (see IRB)  
IGRA  interferon gamma release assay  
Informed consent  A process by which a participant  voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s  decision to participate. Informed conse nt is 
documented by means of a written, signed and dated informed consent form . 
INR international normalized ratio  
  
 
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 103 investigational 
product  (IP) A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
IRB Institutional Review Board (IRB), also called Independent Ethics Committee (IEC) or 
Ethical Review Board (ERB)  
ISR injection site reaction  
IWRS  interactive web -response system  
LLDAS  Lupus Low Disease Activity State  
LTBI  latent tuberculosis infection  
MAD  multiple -ascending dose  
MDRD  Modification of Diet in Renal Disease  
MedDRA  Medical Dictionary for Regulatory Activitie s 
MMRM  mixed -effects model of repeated measures  
NK natural killer  
NONMEM  nonlinear mixed effects modeling  
NRI nonresponder imp utation  
NSAID  nonsteroidal anti -inflammatory drug  
PA posterior –anterior  
participant  Equivalent to Clinical Data Interchange Standards Consortium (CDISC) term “subject,” 
meaning an individual who participates in a clinical trial, either as recipient of an 
investigational medicinal product or as a control.  
In this protocol, the term “participant ” is used to indicate an individual who participates 
in a clinical trial, either as a recipient of an investigational medicinal product or as a 
control. This usage re flects preferences indicated by patient advocates to more 
accurately reflect the role of people who take part in clinical trials.  
PEG  polyethylene glycol  
PGA  Physician’s Global Assessment  
PK/PD  pharmacokinetics/pharmacodynamics  
  
PK pharmacokinetic  
PPD purified protein derivative  
PRO/ePRO  patient -reported outcomes/electronic patient -reported outcomes  
Q2W  every 2 weeks  
QIDS -SR16  16-Item Quick Inventory of Depressive Symptomatology –Self Report  
QTc corrected QT interval  
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 104   
 
RNA  ribonucleic acid  
SAD  single -ascending dose  
SAE serious adverse event  
SAP statistical analysis plan  
SC subcutaneous  
screen  The act of determining if an individual meets minimum requirements  to become part of 
a pool of potential candidates for participation in a clinical study.  
SELENA -SLEDAI  Safety of Estrogens in Lupus National Assessment  – Systemic Lupus Erythematosus 
Disease Activity Index  
SLE systemic lupus erythematosus  
SLEDAI  System ic Lupus Erythematosus Disease Activity Index  
SoA Schedule of Activities  
SOC  system organ class  
SRI-4 Systemic Lupus Erythematosus Responder Index -4 
SRI-5 Systemic Lupus Erythematosus Responder Index -5 
study drug  See “study intervention”  
study intervention  Any investigational intervention, marketed product, placebo, or medical device 
intended to be administered to a study participant according to the study protocol  
TB tuberculosis  
TBL total bilirubin level  
TEAE  Treatment -emergent adverse event: An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with t his treatment.  
TST tuberculin skin test  
ULN upper limit of normal  
WBC  white blood cell   
WOCBP  women of childbearing potential ( see Appendix 10.4.1 .) 
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 105 11. References  
Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for Fatigue. 
Measurement of fatigue in systemic lupus erythematosus: a systematic review. Arthritis 
Rheum . 2007;57(8):1348 –1357.  https://doi.org/  10.1002/art.23113  
[APA] American Psychiatri c Association. Diagnostic and Statistical Manual of Mental 
Disorders . 5th ed. Arlington, VA: American Psychiatric Publishing. ; 2013 . 
 
 
 
Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons  and modeling tech niques  in 
dose-response studies . Biometrics . 2005; 61(3):738 -748. https://doi.org/ 10.1111/j.1541 -
0420.2005.00344.x  
 
 
 
 
 
 
 
 
  
[Columbia Lighthouse Project.] The Columbia Protocol for Research. Columbia -Suicide 
Severity Rating Scale Scoring and Data Ana lysis Guide. Version 2.0. Available at: http://  
cssrs.columbia.edu/wp -content/uploads/ScoringandDataAnalysisGuide -for-Clinical -Trials -
1.pdf. Accessed 30 January 2019  
Cooper GS, Treadwell EL, St Clair EW, et al. Sociodemographic associations with early dise ase 
damage in patients with systemic lupus erythematosus. Arthritis Rheum . 2007;57(6):993 –999. 
https://doi.org/  10.1002/art.22894  
 
 
 
[FDA] Office of Clinical  Pharmacology Division of Pharmacometrics. “Request for 
Qualification of MCP -Mod as an efficient statistical methodology for model -based design and 
analysis of Phase II dose finding studies under model uncertainty.” FDA (2015).  Available at: 
https:  //www.f da.gov  /media/99313/download. Accessed January  27, 2020.  
[FDA] Food and Drug Adminis tration. Guidance for industry:  pharmacokinetics in patients with 
impaired renal function – study design, data analysis, and impact on dosing and labeling; 2010.  
Available at: https://www .fda.gov/media/78573/download. Access ed January  27, 2020.  
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 106 Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease 
Activity State (LLDAS). Ann Rheum Dis . 2016;75:1615 –1621.  https ://doi.org/  
10.1136/ann rheumdis -2015 -207726  
Furie R, Khamashta M, Merrill JT, et al. Anifrolumab, an anti –interferon -α receptor monoclonal 
antibody, in moderate -to-severe systemic lupus erythematosus. Arthritis Rheumatol . 
2017;69 (2):376–386. https://doi.org/10.1002/art.39962  
Furie R, Petri M, Zamani O, et al.  A phase III, randomized, placebo -controlled study of 
belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator , in patients with 
systemic lupus erythematosus . Arthritis Rheum . 2011;63(12):3918 –3930. https://doi.org/  
10.1002/art.30613  
Gladman DD, Urowitz MB, Kagal A, Hallett D. Accurately describing changes in disease 
activity in Systemic Lupus Erythematosus. J Rheumatol . 2000;27(2):377 -379.  
Gould A L. BMA -Mod: A Bayesian model  averaging strategy for determining dose -response 
relationships in the presence of model uncertainty.  Biom  J. 2019; 61(5):1141 -1159.  
https://doi.org/  10.1002/bimj.201700211  
He J, Zhang R, Shao M, et al. Efficacy  and safety of low -dose IL -2 in the treatment of systemic 
lupus erythematosus: a randomised, double -blind, placebo -controlled trial. Ann Rheum Dis . 
2020 ;79(1):141 -149. https ://doi.org/ 10.1136/annrheumdis -2019 -215396  
He J, Zhang X, Wei Y, et al. Low -dose i nterleukin -2 treatment selectively modulates CD4(+) T 
cell subsets in patients with systemic lupus erythematosus. Nat Med . 2016;22(9):991 –993. 
https://doi.org/  10.1038/nm.4148  
 
 
 
Hochberg MC. Updating the American College of Rheumatology revised criteria for the 
classification of systemic lupus erythematosus. Arthritis R heum . 1997;40(9):1725.  
https://doi.org/ 10.1002/art.1780400928  
Isenberg DA, Petri M, Kalunian K, et al. Efficacy and safety of subcutaneous tabalumab in 
patients with systemic lupus erythematosus: results from ILLUMINATE -1, a 52 -week, phase 
III, multicentr e, randomised, double -blind, placebo -controlled study. Ann Rheum Dis . 
2016;75(2):323 –331. https://doi.org/  10.1136/annrheumdis -2015 -207653  
Kalunian K, Urowitz M, Isenberg D, et al. Clinical trial parameters that influence outcomes in 
lupus trials that use the systemic lupus erythematosus responder index. Rheumatology  
(Oxford) . 2018;57(1):125 –133. https://doi.org/ 10.1093/rheumatology/kex368  
Merrill JT, van V ollenhoven RF, Buyon JP, et al.  Efficacy and safety of subcutaneous 
tabalumab, a monoclonal antibody to B-cell activating factor, in patients with  systemic lupus 
erythematosus: results from ILLUMINATE -2, a 52 -week, phase III, multicentre, randomised, 
double -blind, placebo -controlled study. Ann Rheum Dis . 2016;75(2):332 –340. https://doi.org/  
10.1136/annrheumdis -2015 -207654  
CCI
CONFIDENTIAL  Protocol J1P -MC-KFAJ (a) 
 107 Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients 
with active systemic lupus erythematosus: a randomised, placebo -controlled, phase 3 trial. 
Lancet . 2011;377 (9767) :721–731. https://doi.org / 10.1016/S0140 -6736(10)61354 -2 
Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol . 
2015;45(2):344 -355. https://doi.org/  10.1002/eji.201344280  
Özel F, Argon G. The effects of fatigue and pain on daily life activities in sy stemic lupus 
erythematosus. Agri. 2015;27(4):181 –189. https://doi.org/  10.5505/agri.2015.38278  
Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low -dose 
interleukin -2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis . 
2019;78(2):209 –217. https://doi.org/ 10.1136/annrheumdis -2018 -214229  
Sampson HA, Muñoz -Furlong A, Campbell RL, et al. Second symposium on the definition and 
management of anaphylaxis: summary report –Second National Institute of Allergy and 
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin 
Immunol . 2006;117(2): 391–397. https://doi.org/  10.1016/j.jaci.2005.12.1303  
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic 
lupus erythematosus. Arthritis Rheum . 1982;25(11):1271 –1277.   
van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and safety of ustekinumab, an IL -12 
and IL -23 inhibitor, in patients with active systemic lupus erythematosus: results of a 
multicentre, double -blind, phase 2 , randomised, controlled study.  Lancet . 
2018;392 (10155) :1330 –1339. https://doi.org/ 10.1016/S0140 -6736(18)32167 -6 
von Spee -Mayer C, Siegert E,  Abdirama D, et al. Low-dose interleukin -2 selectively corrects 
regulatory T cell defects in patients with systemic lupus erythematosus. Ann Rheum Dis . 
2016 ;75(7):1407 –1415.  https://doi.org/  10.1136/annrheumdis -2015 -207776  
Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib fo r systemic lupus eryt hematosus:  a 
double -blind, randomised, placebo -controlled, phase 2 trial. Lancet . 2018;392 (10143) :222–
231. https://doi.org/ 10.1016/S0140 -6736(18)31363 -1 
Ware JE Jr, Sherbourne CD. The MOS 36 -item short -form health survey (SF -36): I. Conceptual 
framework a nd item selection. Med Care . 1992;30(6):473 -483.  
Winthrop KL, Novosad SA, Baddley JW, et al. Opportunistic infections and biologic therapies in 
immune -mediated inflammatory diseases: consensus recommendations for infection reporting 
during clinical trials and postmarketing surveillance. Ann Rheum Dis.  2015;74(12):2107 -2116.  
https://doi.org/ 10.1136/annrheumdis -2015 -207841  
Yurkovich M, Vostretsova K, Chen W, Aviña -Zubieta JA. Overall and cause -specific mortality 
in patients with systemic lupus erythematosus: a meta -analysis of observational studies. 
Arthritis Care Res  (Hoboken) . 2014;66(4):608 –616. https://doi.org/  10.1002/acr.22173  